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FUNCTION OF ZNF668 IN CANCER DEVELOPMENT 
 
Publication No. ________ 
Ruozhen Hu, M.S. 
Supervisory Professor: Shiaw-Yih Lin, Ph.D. 
Human cancer develops as a result of accumulation of mutations in 
oncogenes and tumor suppressor genes. Zinc finger protein 668 (ZNF668) has 
recently been identified and validated as one of the highly mutated genes in 
breast cancer, but its function is entirely unknown. Here, we report two major 
functions of ZNF668 in cancer development. 
(1) ZNF668 functions as a tumor suppressor by regulating p53 
protein stability and function. We demonstrate that ZNF668 is a nucleolar 
protein that physically interacts with both MDM2 and p53. By binding to MDM2, 
ZNF668 regulates MDM2 autoubiquitination and prevents MDM2-mediated p53 
ubiquitination and degradation; ZNF668 deficiency impairs DNA damage-
induced p53 stabilization. Notably, ZNF668 effectively suppresses breast cancer 
cell proliferation and transformation in vitro and tumorigenicity in vivo. 
Consistently, ZNF668 knockdown readily transforms normal mammary epithelial 
cells. Together, our studies identify ZNF668 as a novel breast tumor suppressor 
gene that acts at least in part by regulating the stability and function of p53.  
(2) ZNF668 functions as a DNA repair protein by regulating histone 
acetylation. DNA repair proteins need to access the chromatin by chromatin 
 v
modification or remodeling to use DNA template within chromatin. Dynamic 
posttranslational modifications of histones are critical for cells to relax chromatin 
in DNA repair. However, the precise underlying mechanism mediating enzymes 
responsible for these modifications and their recruitment to DNA lesions remains 
poorly understood. We observed ZNF668 depletion causes impaired chromatin 
relaxation as a result of impaired DNA-damage induced histone H2AX hyper-
acetylation. This results in the decreased recruitment of repair proteins to DNA 
lesions, defective homologous recombination (HR) repair and impaired cell 
survival after DNA damage, albeit with the presence of a functional ATM/ATR 
dependent DNA-damage signaling cascade. Importantly, the impaired loading of 
repair proteins and the defect in DNA repair in ZNF668-deficient cells can be 
counteracted by chromatin relaxation, indicating that the DNA-repair defect that 
was observed in the absence of ZNF668 is due to impeded chromatin 
accessibility at sites of DNA breaks. Our findings therefore identify ZNF668 as a 
key molecule that links chromatin relaxation with response to DNA damage in 
the control of DNA repair. 
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PART I.  ROLE OF ZNF668 IN P53 REGULATION AND BREAST CANCER 
TUMORIGENESIS 
 
CHAPTER 1 INTRODUCTION 
 
1.1 Breast Cancer and Genetic Aberrations 
Breast cancer continues to be the leading cause of cancer death in 
women in the United States and worldwide (Jemal et al., 2010). It is expected to 
account for 15% of all female cancer deaths in United States in 2010 (Jemal et 
al., 2010). The main types of breast cancer are ductal carcinoma and lobular 
carcinoma. The development of breast cancer is often attributed to many risk 
factors including sex, age, higher hormone levels, race and family history of 
breast cancer (McPherson et al., 2000). 
Breast cancer development, like other types of cancer, is the 
consequence of the accumulation of multiple gene mutations (Wooster et al., 
2003). Breast cancer risk is typically increased in individuals with family history. 
Although researchers found that the mutations in high-penetrance BRCA1 and 
BRCA2 genes contribute to breast cancer development, these mutations only 
account for less than 20% of the patients with familial risk (Anglian Breast 
Cancer Study Group, 2000; Wooster et al., 2003). These findings suggest that 
additional genetic alterations are required for the development of breast cancer. 
Identifying these relatively low-penetrance genes will help people to better 
understand the implication of genetic alterations in breast cancer development.   
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The high-throughput genotyping analysis and understand of genetic 
variation patterns in human genome have advanced the research of genetic 
abberiations in human cancer. The availability of the human genome sequence 
highthroughput analysis of tumor genome, and powerful computational methods 
make it possible to identify new candidate cancer genes and somatic changes in 
human cancers. For example, researchers investigated the genetic alterations in 
the coding sequences of well annotated genes and they identified the regions of 
the genome that have the potential to cause cancer development (Sjoblom et al., 
2006; Wood et al., 2007). These studies will facilitate the design of targeted 
therapeutic approaches and provide key insights into the mechanisms 
underlying tumorigenesis. 
 
1.2   Zinc Finger Protein 668 and its somatic mutations in patient breast 
cancer samples  
The accumulation of mutations in oncogenes and tumor suppressor 
genes accounts for human cancer development (Vogelstein and Kinzler 2004). 
Thus, understanding how these genetic alterations contribute to human cancer 
development is a powerful tool to study the mechanisms underlying 
tumorigenesis and to identify new targets for clinical intervention. 
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Figure 1. Ten leading cancer types for the estimated new cancer cases and 
deaths by sex, 2010. (Jemal et al., 2010). 
 
 
Through genomewide gene sequencing, many genes that are frequently 
mutated in breast tumor samples have been discovered (Sjoblom et al., 2006). 
Among these mutated genes, a hypothetical protein (FLJ13479) later named 
zinc finger protein 668 (ZNF668) was identified, and validated as a frequently 
mutated gene in breast cancer (Sjoblom et al., 2006). ZNF668 gene mutations 
were found in four out of thirty-five breast cancer samples analyzed (11.4%) 
(Sjoblom et al., 2006). Since ZNF668 is frequently mutated in breast cancer, we 
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suspect that ZNF668 might be an important breast cancer gene that contributes 
to breast cancer development. 
 
 
 
Figure 2. Conserved domain in zinc finger protein 668. 
 
 
ZNF668 belongs to the kruppel C2H2-type zinc-finger protein family and 
contains 16 C2H2-type zinc fingers (Figure 2). So far, the function of ZNF668 
has remained entirely unexplored. To understand the role of ZNF668 in breast 
cancer development, we used a proteomics-based approach to systematically 
identify ZNF668-binding proteins (Figure 3). A nucleolar protein, nucleophosmin 
(NPM, B23), was pulled down by ZNF668 (Figure 3), and interaction between 
ZNF668 and NPM was confirmed by immunoprecipitation analysis later. 
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Figure 3. Silver staining of the ZNF668 complex separated by SDS-PAGE. The 
whole cell extracts were prepared from U2OS cells transiently transfected with 
empty vector or Flag-ZNF668. Cell lysates were mixed with M2-Flag agrose 
beads and the protein complex was pulled down and eluted with M2-Flag 
peptide. Flag-ZNF668 and nucleophosmin are indicated. 
 
 
1.3  Role of nucleolus and nucleolar proteins in p53 regulation and 
tumorigenesis.  
The connection between nucleolus function and tumorigenesis is now 
being appreciated. Although nucleolus is well known as the site for production 
and assembly of ribosome components, recent studies suggested that nucleolar 
components were also involved in cancer development events such as p53 
stabilization and p53 induced cell cycle arrest (Lohrum et al., 2003; Dai et al., 
2006 and Pestov et al., 2001).  
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NPM is a nucleolar phosphoprotein that constantly shuttles between the 
nucleus and cytoplasm (Yun et al., 2003; Grisendi et al., 2006). It is involved in 
ribosome biogenesis and can function as either an oncogene or a tumor 
suppressor depending on the context (Grisendi et al., 2006). Recent studies 
showed that NPM was involved in regulation of the p53 tumor suppressor 
protein function (Colombo et al., 2002; Kurki et al., 2004). NPM binds MDM2 and 
protects p53 from MDM2-mediated degradation (Kurki et al., 2004). The 
nucleolus, where most NPM resides, functions as a cellular stress sensor that 
integrates a variety of cellular stresses to trigger p53 responses and regulate the 
role of p53 in tumor suppression (Pestov et al., 2001; Rubbi and Milner 2003; 
Horn and Vousden 2004); the nucleolus plays an important role in p53 
stabilization under stress conditions (Pestov et al., 2001). Indeed, subcellular 
redistribution of NPM and other nucleolar proteins, such as ARF, has regulated 
p53 function (Itahana et al., 2003; Bertwistle et al., 2004; Kurki et al., 2004; 
Korgaonkar et al., 2005; Grisendi et al., 2006).  
The nucleolar ARF-MDM2-p53 feedback loop regulation also represents 
another example to explain the connection between nucleolar stress and 
tumorigenesis. Tumor suppressor ARF is a nucleolar protein and its association 
with MDM2 could contribute to the localization and retention of MDM2 to the 
nucleolus thereby sequester MDM2 activity and stabilize p53 (Zhang et al., 1998; 
Sherr et al., 2000; Honda et al., 1999; Kamijo et al., 1999; Stott et al., 1998 and 
Pomerantz et al., 1998). Under cellular stress, disruption of the nucleolar 
function is responsible for the redistribution of nucleolar proteins to stabilize and 
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regulate p53 function (Rubbi et al., 2003). Therefore, the nucleolus is proposed 
to be a sensor for integrating variety of cellular stresses together to trigger p53 
responses and regulate its role in tumorigenesis (Pestov et al., 2001; Rubbi et 
al., 2003 and Horn et al., 2004).  
Thus, the connection between nucleolus and regulation of p53 is highly 
implicated in tumorigenesis. The interaction between ZNF668 and NPM and the 
nucleolar localization of ZNF668 (see Figure 4) suggested that ZNF668 might be 
involved in p53 regulation. 
 
1.4     p53 and tumor suppression 
The tumor suppressor protein p53 was first identified in 1979 as a cellular 
protein that bound to the simian virus (SV40) large T antigen and accumulated in 
the nuclei of cancer cells (Lane et al., 1979). The real role of p53 was uncovered 
until 10 years after its discovery. At first, p53 was thought to be an oncogene 
because it present at increased levels in transformed cells (Vogelstein, 2001). 
However, later it was found that the p53 people were studying was in fact a 
mutant form because the p53 cDNA was cloned from cancer sample and it 
contained missense mutations. Since 1989, research into p53 supported that 
one of the major function of wild type p53 was tumor suppression.  
In normal cells, p53 level is tightly controlled by its negative regulator, the 
E3 ubiquitin ligase MDM2 (Haupt et al., 1997; Kubbutat et al., 1997; Nampoothiri 
1998; Kubbutat, et al. 1999). Ubiquitination of p53 by MDM2 leads to export of 
p53 from the nucleus to the cytoplasm followed by proteasomal degradation 
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(Boyd et al., 2000; Geyer et al., 2000). Under cellular stresses—such as genetic 
alterations, DNA damage stress, oncogene activation, and hypoxia—
dissociation of MDM2 and p53 stabilizes p53 protein, and stabilization of p53 in 
turn leads to various cellular responses, including cell apoptosis, cell cycle 
arrest, cell senescence and DNA damage repair (Vousden and Lu 2002). 
p53 plays a critical role in preventing damaged cells from transforming 
into malignant cells (Ryan et al., 2001). The most important pathways involved in 
tumor suppression that are activated by p53 include apoptosis, cell-cycle arrest, 
senescence and DNA repair.  
If the DNA damage is too severe to be repaired, the activated p53 can 
initiate cell apoptosis, the programmed cell death (Jian et al., 2003). The p53 
induced apoptosis can be explained by its activation of expression of various 
downstream target genes including p53AIP, bax, Fas/APO1, Tsp1, IGF-BP3, 
PUMA and others (Hickman et al., 2002). The activated p53 activates 
expression of p21 which is an inhibitor of cyclin-dependent kinases (CDKs). p21 
binds to G1-to-S CDK complexes and inhibits G1-to-S transition (Harper et al., 
1993). p53 may also inhibit G2-to-M transition by regulation of protein 14-3-3σ, 
which sequesters cyclin B1–CDK1 complexes outside the nucleus and stop cells 
in G2 phase (Hermeking et al., 1997). In tumors, mutant p53 can no longer bind 
DNA in an effective way and the downstream regulation of p21 failed to stop cell 
division, thus contributed to tumor formation by the uncontrolled cells division. 
DNA damage, oncogene activation or telomere dysfunction can lead to 
the activation of p53 (Deng et al., 2008). Activated p53 can trigger senescence, 
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a permanent cell cycle arrest, and inhibit tumor progression. Senescence is 
likely to result from changes in the expression of a number of proteins such as 
the plasminogen activator inhibitor 1 (PAI-1) (Kortlever et al., 2006). p21 is 
another important player in response to p53-mediated senescence (Harper et 
al., 1993). In mouse models, reactivation of p53 in carcinomas and sarcomas 
triggers senescence rather than apoptosis (Artandi et al., 2005). In vivo study 
indicated that p53 induced senescence caused the subsequent engagement of 
the immune system and could result in tumor clearance (Xue et al., 2007). 
The p53 protein is important in maintaining genetic stability. It may involve 
the induction of genes that regulate nucleotide-excision repair of DNA (Seo et 
al., 2002), chromosomal recombination and chromosome segregation. Further 
evidence for a role for p53 in DNA repair comes from the induction of a specific 
ribonucleotide reductase gene (p53R2) by p53 after DNA damage (Xue et al., 
2007). p53 may also facilitate the homologous recombination repair of double 
strand breaks through the regulation of the fidelity of Rad51-dependent HR 
repair pathway (Bertrand et al., 2004). 
 
1.5      Hypothesis and project goals 
In our preliminary data, ZNF668 was associated with many nucleolar 
proteins including, nucleophosmin (NPM) and nucleostemin (NS), two proteins 
that bind and regulate p53 protein. We also identified ZNF668 as a novel p53 
binding protein localized in the nucleoli of breast cancer cells. Therefore, we 
hypothesize that ZNF668 plays a critical role in regulation of p53 tumor 
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suppressor activity for breast tumor suppression. We suspect that ZNF668 may 
contribute to breast cancer suppression at least in part through regulation of 
p53. 
In this part of study, we aim to demonstrate the functional interaction 
among ZNF668, p53, and MDM2. We will try to study the role of ZNF668 as a 
novel tumor suppressor gene in breast cancer and reveal its mechanistic 
function in regulating the MDM2-p53 interaction. 
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CHAPTER 2 MATERIALS AND METHODS 
 
2.1 Cell Culture and Transfection 
U2OS cells and breast cancer cells were purchased from the American 
Type Culture Collection. U2OS cells were maintained in McCoy's 5A medium 
(Cellgro) supplemented with 10% fetal bovine serum (FBS) with glutamine, 
penicillin, and streptomycin. MCF7, MCF7-control, and MCF7-p53 knockdown 
cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Cellgro) 
supplemented with 10% FBS with glutamine, penicillin, and streptomycin. 
MCF10A cells were maintained in mammary epithelial growth medium 
(Clonetics), a proprietary serum-free medium containing insulin, hydrocortisone, 
epidermal growth factor, and bovine pituitary extract. HMECs were grown in 
mammary epithelial basal medium supplemented with MEGM SingleQuots 
growth factors (Lonza). Cells were incubated at 37°C in a humidified incubator 
with 5% CO2 and transfected with Fugene 6 (Roche), Lipofectamine 2000 
(Invitrogen) or Oligofectamine (Invitrogen). 
 
2.2 Plasmids 
To generate FLAG-ZNF668, V5-ZNF668, and GST-ZNF668 constructs, 
full-length ZNF668 cDNA was amplified by polymerase chain reaction (PCR) 
and subcloned into pCMV5-3 x FLAG vector (Sigma), pLenti4/TO/V5-DEST 
vector (Invitrogen), and pGEX-4T vector (Addgene). The R556Q (Mutant 1) and 
A66T (Mutant 2) point mutations were created from 3 x FLAG-ZNF668 using the 
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GeneTailor Site-Directed Mutagenesis System (Invitrogen). The FLAG-tagged 
ZNF668 deletion mutants ZNF668- Δ 1~ Δ 12 were generated by PCR and 
subcloned into 3 x FLAG vector. FLAG-p53 (108038, pcDNA3 FLAG-p53), GST-
p53 (10852, p3113 GST-p53), and GST-MDM2 (16237, pGEX-4T MDM2 wild-
type) were purchased from Addgene. MDM2 deletion plasmids Δ 58-89, Δ 212-
296, Δ 222-437, Δ 296-437, and Δ 9 (RING finger domain deletion) were kind 
gifts from Dr. Karen Vousdens (The Beatson Institute for Cancer research). The 
identity of the plasmids was confirmed by sequencing at the MD Anderson 
Cancer Center DNA Analysis Core Facility. 
 
2.3 Antibodies and Reagents 
Nucleotides 548-1449 were subcloned into pGEX-4T with the sense 
primer 5 -TTTTGGATCCATGGAAGTGGAGGCTGCAGAG-3  and the antisense 
primer 5 -TTTTGAATTCGCGCTGGTGGCGAGGGAAGCT-3 , and the protein 
product was used for immunization for rabbit polyclonal anti-ZNF668 antibody 
(Proteintech Group, Inc.). Anti-FLAG M2-agarose affinity gel was purchased 
from Sigma. Anti-p53 (FL-393), anti-MDM2 (SMP14), anti-NPM (C-19), anti-p53 
(FL393), and anti-p21(C-19) were purchased from Santa Cruz Biotechnology. 
Anti-p53 (DO-1) was purchased from Calbiochem. Anti-phospho-p53–Ser 15 
was purchased from Cell Signaling. Anti-ubiquitin (FK2) and an ubiquitinylation 
kit were purchased from BioMol. Anti-NS (MAB4311) was purchased from 
Chemicon. Anti-V5 (ab9116) and anti-NPM (ab10530) were purchased from 
Abcam. Fluorochrome-conjugated secondary antibodies were purchased from 
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Jackson ImmunoResearch Laboratories. A thrombine cleavage capture kit was 
purchased from Novagen. Cycloheximide was obtained from Sigma and used at 
50 μg/ml (U2OS cells) or 20 μg/ml (MCF7 cells). MG132 (carbobenzoxy-L-
leucyl-L-leucyl-L-leucine) was obtained from EMD Biosciences and used at 10 
μM. Nutlin-3 was purchased from Cayman Chemical and used at 10 μM. 
 
2.4 RNA Interference 
ZNF668 knockdown was achieved by RNA interference using either 
siRNA (Dharmacon) or a lentiviral vector-based MISSION shRNA (Sigma). The 
ON-TARGETplus ZNF668 siRNA duplex and ON-TARGETplus SMARTpool 
HDM2 siRNA mix were purchased from Dharmacon Research, Inc. ON-
TARGETplus nontargeting siRNA was used as a control for the siRNA reactions. 
RNA duplexes (final concentration 100 nM) were transfected into the cells using 
Oligofectmine (U2OS) or Lipofectamine 2000 (MCF7 & MCF10A) according to 
the manufacturer’s protocol (Invitrogen). Cells transfected with ZNF668 siRNA 
duplexes were incubated for 2 and 3 days, respectively. A decrease in the 
respective protein levels was verified by Western blotting. Lentiviral particles 
corresponding to the MISSION shRNA ZNF668 target set were used, as well as 
the MISSION nontarget shRNA control. The specificity and efficacy of the 
shRNA ZNF668 procedure were controlled with Western blotting after 
transduction and puromycin selection in knockdown cells. 
 
2.5 Immunofluorescent Microscopy 
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Cells were fixed with 4% paraformaldehyde and then permeabilized with 
0.5% NP-40 and 1% Triton X-100. The primary antibodies were as follows: 
NPM, C-19; NS, MAB4311; V5-tag, ab9116; p53, FL393; and MDM2, SMP14. In 
coimmunostainings, donkey anti-rabbit conjugated Alexa 594, goat anti-rabbit 
conjugated Alexa 488, chicken anti-mouse conjugated Alexa 594, or goat anti-
mouse conjugated Alexa 488 (Invitrogen) were used as fluorochromes, and DNA 
was stained with 4 ,6-diamidino-2-phenylindole (DAPI, Vector Laboratories). 
Absence of cross-reactivity of the antibodies and conjugates was verified in 
separate experiments. Images were acquired using a Nikon Eclipse TE200-E 
microscope and processed with IPLab imaging software (BioVision 
Technologies). 
 
2.6 Immunoblotting and Immunoprecipitation 
Cells were washed in phosphate-buffered saline and lysed in modified 
RIPA buffer (50 mM Tris-HCl [pH 7.4], 1% NP-40, 10% sodium deoxycholate, 
150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium 
orthovanadate, and 1 mM NaF). For nuclear extract preparation, cells were lysed 
in (10 mM HEPES [pH 8.0], 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, 
and 0.5% NP-40), and nuclear extracts were prepared in nuclear extraction 
buffer (20 mmol/L HEPES [pH 7.9], 1.5 mM MgCl2, 100 mM KCl, 420 mM NaCl, 
0.2 mM EDTA, and 1 mM dithiothreitol). After clarification, cell lysates were 
immunoprecipitated with specific antibodies (NPM, ab10530; ZNF668, rabbit 
polyclonal anti-ZNF668 antibody; MDM2, SMP-14; and p53, DO-1). The 
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immunocomplexes were collected on Protein A/G plus-conjugated agarose 
beads (Santa Cruz Biotechnology). Cellular lysates or immunocomplexes were 
separated by 7% or 12% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to Protran nitrocellulose 
membrane (Fisher Scientific). Membranes were blocked in Tris-buffered saline-
0.1% Tween 20 (TBS-T)/5% (w/v) milk for 1 h at room temperature and were 
then incubated with primary antibodies diluted in TBS-T/5% (w/v) milk for 2 h at 
room temperature or overnight at 4°C. Subsequently, membranes were washed 
with TBS-T and incubated with horseradish peroxidase secondary antibody 
(1:5000) (Jackson ImmunoResearch) diluted in TBS-T/5% skim milk. 
Membranes were washed in TBS-T, and bound antibody was detected by 
enhanced chemiluminescence (GE Healthcare). 
 
2.7 In Vivo Ubiquitination Assay 
For the in vivo p53 ubiquitination assay, FLAG-tagged ZNF668 was 
transfected into U2OS cells using Fugene 6 (Roche). Forty-eight hours after 
transfection, cells were treated with MG132, harvested, washed with phosphate-
buffered saline, pelleted, and lysed in RIPA buffer. The cell lysates were then 
subjected to SDS-PAGE, and p53 or MDM2 protein level was normalized so that 
there were equal levels of p53 or MDM2 in control cells and ZNF668-expressing 
cells. The proportional amounts of cell lysates were incubated with p53 or MDM2 
antibody and pulled down using protein A/G beads. Beads were washed three 
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times and boiled for 5 min. The boiled samples were separated by SDS-PAGE, 
and protein was detected by immunoblotting with anti-ubiquitin antibody. 
 
2.8 Preparation of Recombinant Proteins 
The plasmids pGEX-4T-1-ZNF668, pGEX-4T-MDM2, and pGEX-2TK-p53 
were used to express recombinant GST-ZNF668, GST-MDM2, and GST-p53 in 
Escherichia coli strain BL21 (GE Healthcare). The GST fusion proteins were 
expressed by induction for 12 h at 25°C with 0.1 mM isopropyl-1-thio-β-D-
galactopyranoside in strain BL21 and purified using glutathione agarose (Sigma) 
according to the manufacturer's instructions. GST fusion proteins harboring p53, 
ZNF668, and MDM2 were cleaved and purified with a thrombin cleavage capture 
kit. 
 
2.9 In Vitro GST-Protein Binding Assay 
Cleaved p53 and MDM2 were purified as described in the preceding 
paragraph. GST-ZNF668 was not cleaved. Purified proteins were incubated in 
300 ml of binding buffer (25 mM Tris-Cl [pH 7.2], 50 mM NaCl, and 0.2% NP-40) 
with continuous shaking. Proteins were recovered (2 h at 4°C) with glutathione 
agarose beads (Sigma). Beads were washed three times with 1 ml of washing 
buffer (100 mM Tris-Cl [pH 8.0], 100 mM NaCl, and 1% Nonidet P-40) four times 
and were eluted with 10 mg/ml fresh-made reduced glutathione (pH 8.0). Eluted 
proteins were subjected to SDS-PAGE and Western blotting analysis. 
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2.10 Reverse Transcriptase-PCR and PCR 
cDNA was transcribed using SuperScript III (Invitrogen) following the 
manufacturer's instructions. ZNF668 was amplified by PCR using the primers 5 -
GGAAGCCAGTGGGGAGAAGGTGTC-3  and 5 -CGCTCGTGGCTCTGGTA 
GGAACTG-3 . For amplification of p53, the primers 5 -GCGCACAGA 
GGAAGAGAATC-3  and 5 -CCTCATTCAGCTCTCGGAAC-3  were used. 
 
2.11 Luciferase Assay 
U2OS cells were transfected with the pG13-LUC reporter vector in the 
absence or presence of expression vectors for the indicated proteins or empty 
expression vector (3 FLAG). The total amount of expression vector was 
constant in all transfections. After 48 h, luciferase activities were determined in 
duplicate samples according to the manufacturer’s instructions (Promega). The 
relative luciferase activity was assayed by cotransfection of a plasmid for the 
expression of renella and normalization for its activity. The fold increase in 
relative luciferase activity therefore represented the extent of p53 activation. 
Data were presented as the mean ± standard deviation (SD) of three 
independent experiments. 
 
2.12 In Vitro Proliferation and Soft Agar Assay 
To measure cell proliferation, cells were plated in 96-well plates (200-μl 
cell suspensions, 5x103 cells/ml) and allowed to grow for 1 to 4 days. Each day, 
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT; Sigma) 
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substrate (2 mg/ml) was added into the culture medium. Four hours later, the 
culture medium was removed, and dimethyl sulfoxide was added. The optical 
density was measured spectrophotometrically at 490 nm. Each experiment was 
repeated at least three times. 
For soft agar assay, cells were resuspended in DMEM containing 0.35% 
agarose (ISC BioExpress, GenePure LE) and 10% FBS and seeded onto a 
coating of 0.5% agarose in DMEM containing 10% FBS. Colonies were counted 
2 to 4 weeks after preparation. 
 
2.13 Tumor Growth in Nude Mice 
Six-week-old female nude mice were used for experiments. All animal 
studies were conducted in compliance with animal protocols approved by the 
MD Anderson Institutional Animal Care and Use Committee. Before injection of 
estrogen receptor-positive MCF7 cells, mice were implanted subcutaneously 
with 0.72 mg of 17-β-estradiol 60-day release pellets (E2 pellet; Innovative 
Research of America). Mice were injected in the mammary glands with 2 x 106 
cells from various cell lines in 100 μl of phosphate-buffered saline. After 1 week, 
tumors were measured every 3 days. Each cell line was tested in five different 
animals. Volume was calculated as W2 x L x 0.52. 
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CHAPTER 3 FUNCTION OF ZNF668 IN P53 AND TUMOR PROGRESS 
REGULATION 
 
3.1    ZNF668 localizes in the nucleus, accumulates in the nucleolus, and 
interacts with NPM and nucleostemin 
V5-tagged ZNF668 construct was induced to ectopically express ZNF668 
protein in different breast epithelial cell lines, including MCF7 and MCF10A and 
human mammary epithelial cells (HMECs). Western blotting analysis revealed a 
70- to 80-kD V5-tagged band in all ZNF668-overexpressing cell lines. Through 
motif analysis, two consensus nuclear localization sequences (R/K-R/K-X-R/K) 
were detected in the N-terminal of ZNF668 protein (Figure 4), suggesting that 
ZNF668 is a nuclear protein.  
 
 
Figure 4. Sequence alignment of ZNF668 in different species. Boxed areas 
correspond to the consensus nuclear localization sequence. NPM (B23) and NS 
served as positive controls showing the consensus nuclear localization 
sequence in well-known nuclear proteins. 
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A rabbit polyclonal antibody was raised against a GST-ZNF668 fusion 
protein (aa 183-483) and used for Western blotting analysis. This ZNF668 
antibody also detected a band between 70 and 80 kD with its expression 
enriched in the nuclear fraction (Figure 5). The specificity of our ZNF668 
antibody was verified by small interfering RNA (siRNA) knockdown as well as 
overexpression of V5-tagged ZNF668 (data not shown). 
 
Figure 5.  ZNF668 localizes predominantly in the nucleus. U2OS cells, HMECs, 
and MCF7 cells were lysed in RIPA buffer or nuclear extraction buffer. Lamin 
A/C and α-tubulin served as nuclear and cytoplasmic loading markers, 
respectively. 
 
 
 Immunofluorescence analysis revealed specific nuclear staining for 
ZNF668 with strong signals in one or more nucleolus-like nodular structures in 
both MCF7 and MDA-MB-468 cells (Figure 6, upper two rows). The specificity of 
the staining pattern was supported by V5 antibody staining in MCF7 cells and 
HMECs with overexpression of V5-tagged ZNF668 (Figure 6, lower two rows), 
and the nucleolar localization of ZNF668 was confirmed by ZNF668’s 
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colocalization with two known nucleolar proteins, nucleostemin (NS) and NPM 
(Figure 6). 
 
Figure 6. ZNF668 accumulates in the nucleolus. Upper panel: MCF7 and MDA-
MB-468 cells were stained with antibodies against ZNF668 (red) and NS 
(green). Lower panel: Ectopic V5-tagged ZNF668 was induced in MCF7 cells 
and HMECs by doxycycline treatment. Cells were stained with V5 (green) and 
NPM (red). Nuclei were visualized with DAPI (blue). Scale bars: 20 µm. 
 
 
 To systematically identify proteins involved in ZNF668 function, we 
carried out immunoaffinity purification followed by mass spectrometry. We found 
that NPM was a major ZNF668-associated protein (Figure 3). To validate the 
mass spectrometry result, we performed immunoprecipitation/Western blotting 
analysis and found that ZNF668 co-precipitated with NPM and NS (Figure 7A). 
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The interaction between ZNF668 and NPM was further confirmed by reciprocal 
immunoprecipitation using ZNF668 or NPM antibody (Figure 7B). These results 
were consistent with results on immunofluorescent staining (Figure 6) and 
strongly suggested that ZNF668 localizes in the nucleus, accumulates in the 
nucleolus, and interacts with nucleolar proteins. 
 
 
 
Figure 7. ZNF668 associates with NPM and NS. (A) U2OS cells were 
transfected with empty vector or Flag-ZNF668; 48 h later, cells lysates (3 mg) 
were immunoprecipitated and immunoblotted with antibodies against the 
indicated molecules. (B) Endogenous association between ZNF668 and NPM. 
Cell lysates from MCF7 cells were immunoprecipitated with anti-ZNF668, anti-
NPM, or preimmune IgG and immunoblotted with anti-ZNF668 or anti-NPM 
antibody. 
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3.2      ZNF668 interacts with MDM2 and p53 
It has been shown that NPM and NS bind to and regulate the protein 
stability and function of p53 (Colombo et al., 2002; Tsai and McKay 2002; Kurki 
et al., 2004; Ma and Pederson 2007). Therefore, we performed 
immunoprecipitation/Western blotting analysis to test whether ZNF668 also 
interacted with p53. We found that ZNF668 interacted with p53 when ZNF668 
was ectopically expressed in U2OS human osteosarcoma cells (Figure 8A and 
B). Interestingly, ZNF668 also interacted with the negative regulator of p53, 
MDM2 (Figure 8A and B).  
 
 
Figure 8. ZNF668 interacts with MDM2 and p53. (A) ZNF668 associates with 
MDM2 and p53 in vivo. U2OS cells were transfected with empty vector or Flag-
ZNF668; 48 h later, cells lysates (3 mg) were immunoprecipitated and 
immunoblotted with antibodies against the indicated molecules. (B) Ectopically 
expressed p53 associates with ZNF668. U2OS cells were transfected with 
empty vector or Flag-p53; reciprocally, cells were transfected with empty vector 
or Flag-ZNF668. Forty-eight hours after transfection, cells lysates (3 mg) were 
immunoprecipitated with M2-Flag conjugated beads and immunoblotted with 
antibodies against the indicated molecules. 
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The interactions between ZNF668, p53, and MDM2 were further 
confirmed by reciprocal immunoprecipitation using ZNF668, p53, and MDM2 
antibodies (Figure 9A), supporting the physical interactions among these three 
proteins in cells. In vitro GST-protein binding assay also confirmed the 
interactions among these three proteins (Figure 9B). 
 
 
 
Figure 9. Endogenous ZNF668 interacts with MDM2 and p53. (A) Endogenous 
ZNF668 associates with p53 and MDM2. Cellular lysates of MCF10A cells were 
prepared by lysing the cells with RIPA buffer; immunoprecipitated with anti-
ZNF668, anti-p53, anti-MDM2, or preimmune IgG; and immunoblotted with 
antibodies against the indicated molecules. (B) In vitro interaction between 
ZNF668, MDM2, and p53. GST-MDM2 and GST-p53 constructs were cleaved 
using a thrombin cleavage capture kit. Cleaved MDM2 or p53 was mixed with 
GST-ZNF668 in the binding buffer and incubated overnight at 4°C. Glutathione 
beads were added into the reaction and incubated for 2 h at 4°C; this was 
followed by extensive washing and analysis of the protein complexes by 
Western blotting for the indicated molecules. 
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 To map the binding domain on ZNF668, we expressed FLAG-tagged 
wild-type ZNF668 and ZNF668 mutants lacking different parts of amino acid 
sequences in U2OS cells (Figure 10A). We found that both MDM2 and p53 
could be co-precipitated with wild-type ZNF668, but their binding to ZNF668 with 
N-terminal deletions was much weaker than their binding to ZNF668 with C-
terminal deletions (Figure 10B). Regions aa84-aa190 and aa268-aa367 were 
particularly important for the interaction between MDM2 and ZNF668: when 
these two regions were deleted, the MDM2-ZNF668 interaction was abolished. 
Interestingly, these two regions were also important for the interaction between 
p53 and ZNF668. Notably, immunofluorescent staining showed that the ZNF668 
deletions lacking regions aa84-aa190 and aa268-aa367 were localized 
exclusively outside the nucleolar region, indicating that these two regions 
contain the nucleolar localization signals for ZNF668 (Figure 10C). These results 
identified the interaction domain of ZNF668 required for the interaction with 
MDM2 and p53 and indicated the importance of the nucleolar localization of 
ZNF668 for its interactions with MDM2 and p53. 
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Figure 10. The interaction domain of ZNF668 with MDM2 and p53. (A) Summary 
of the binding of ZNF668 deletions with MDM2 and p53. (B) Mapping of the 
MDM2 and p53 binding domains of ZNF668. FLAG-tagged wild-type ZNF668 
and deletion mutants of human ZNF668 were constructed and individually 
transfected into U2OS cells. After 2 days, the cells lysates (3 mg) were 
immunoprecipitated with M2-FLAG agarose beads and immunoblotted with 
antibodies against the indicated molecules. (C) Immunofluorescent staining of 
FLAG-tagged ZNF668 deletions. U2OS cells were overexpressed with FLAG- 
ZNF668 deletions and stained with antibodies against FLAG (green) and NPM 
(red).  
 
 
 Conversely, we also sought to map the MDM2 domains that are required 
for ZNF668 binding. We expressed MDM2 deletion proteins in U2OS cells that 
constantly expressed FLAG-ZNF668. MDM2 has been shown to bind to p53 
through the N-terminal domain (Kubbutat et al., 1999). Although FLAG-tagged 
ZNF668 was co-precipitated with wild-type MDM2, an MDM2 protein carrying a 
p53 binding domain deletion (MDM2 Δ58-89), and an MDM2 protein carrying a 
C-terminal RING finger deletion (MDM2 Δ9), the interaction between ZNF668 
and an MDM2 protein with the central region deleted (MDM2 Δ222-437) was 
defective (Figure 11A, B and C). In contrast, we confirmed that p53 could form a 
complex with wild-type MDM2, MDM2 Δ9, and MDM2 Δ222–437, but not MDM2 
Δ58-89 (Figure 11C). These results indicated that p53 and ZNF668 bound to 
different regions on MDM2. Further analysis of mutations within the central 
region of MDM2 showed that deletion of aa212-aa296 significantly reduced the 
binding between ZNF668 and MDM2, although deletion of aa295-aa417 did not 
prevent their interaction (Figure 11B). Interestingly, a similar region of MDM2 is 
required for binding to ARF and ribosomal protein L11, suggesting a common 
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mechanism by which different molecules modulate the function of MDM2 
(Bothner et al., 2001; Lohrum et al., 2003). 
 
 
Figure 11. ZNF668 interacts with MDM2 in the central region. (A) Cartoon of the 
MDM2 protein, indicating the position of principal domains and summarizing the 
ZNF668 binding patterns. NLS: nuclear localization signal; NES: nuclear export 
signal; NoLS: nucleolar localization signal. (B) Mapping of the MDM2 binding 
domain of ZNF668. U2OS cells with constant Flag-ZNF668 overexpression were 
transfected with the indicated MDM2 deletion mutants. Twenty-four hours after 
transfection, the cells were lysed and immunoprecipitated with M2-Flag 
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conjugated beads. Associated MDM2 protein was detected by Western blotting. 
(C) Mapping of the MDM2 binding domain for p53 and ZNF668. U2OS cells with 
constant Flag-ZNF668 overexpression were transfected with the indicated 
MDM2 deletion proteins. Twenty-four hours after transfection, the cells were 
lysed and immunoprecipitated using M2-Flag beads or p53 antibody with protein 
A/G agarose beads. Associated MDM2 protein was detected by Western 
blotting. 
 
 
3.3      ZNF668 regulates p53 stability and activity 
Since ZNF668 binds to MDM2 and p53, we next sought to determine 
whether there is a causal relationship between ZNF668 status and p53 protein 
levels. As shown in Figure 12A, when FLAG-tagged ZNF668 was ectopically 
expressed in U2OS cells, we found increased p53 protein level as well as 
increased level of the p53 downstream target p21. p53 mRNA levels were not 
affected suggesting the effects were not on transcription or RNA stability. 
Increased p53 protein expression was also seen when we overexpressed 
ZNF668 in MCF7 cells and HMECs (Figure 12B). 
 
Figure 12. ZNF668 regulates p53 stability and activity. (A) ZNF668 positively 
regulates p53 protein expression without affecting p53 mRNA levels. U2OS cells 
were transfected with empty vector or Flag-ZNF668, and cell lysates were 
harvested and immunoblotted with antibodies against p53 and p21 (left panel) or 
subjected to RT-PCR of p53 (right panel). (B) ZNF668 positively regulates p53 
protein expression in different cell lines. ZNF668 was overexpressed in U2OS 
and MCF7 cells and HMECs. Cell lysates were harvested and analyzed. 
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 To determine whether the increase in the p53 level was regulated at the 
posttranslational level, we treated U2OS cells with cycloheximide to block de 
novo protein synthesis. In these cells, overexpression of ZNF668 increased the 
half-life of p53 protein from 1 h to more than 2 h (Figure 13A and B), suggesting 
a role of ZNF668 in stabilizing p53 protein. Inversely, knockdown of ZNF668 with 
siRNA in MCF7 cells resulted in a decrease of the p53 protein half-life from 2 h 
to 30 minutes (Figure 13C). 
 
Figure 13. ZNF668 regulates p53 protein stability. (A) U2OS cells were 
transfected with empty vector or Flag-ZNF668. Cells were treated with 
cycloheximide (CHX) for the indicated times, and cell lysates were harvested 
and immunoblotted with antibodies against the indicated molecules. (B) 
Quantification (mean of three experiments) of p53 protein levels in control and 
ZNF668-overexpressing U2OS cells. (C) MCF7 cells were transfected with 
control or ZNF668 siRNA. Cells were treated with CHX for the indicated times, 
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and cell lysates were harvested and immunoblotted with antibodies against the 
indicated molecules. Right panel: Quantification of p53 protein levels in control 
and ZNF668-knockdown MCF7 cells.  
 
 
 
 
 To test whether ZNF668 regulates p53 activity, we transfected MCF10A, 
MCF7, and U2OS cells with siRNA targeting ZNF668 and then treated the cells 
with UV radiation (50 J/m2) or γ radiation (10 Gy). Cell lysates were harvested 2 
h later, and the changes in ZNF668 and p53 were analyzed. In U2OS cells, 
depletion of ZNF668 significantly reduced both stress-induced levels of p53 and 
p53 basal levels (Figure 14A). Similar results were observed in MCF10A and 
MCF7 cells (Figures 14B and C). The reduction in the level of p53 in response to 
DNA damage was paralleled by a reduction in phosphorylation of Ser15 of p53 
(Figure 14A), a marker of stress-induced p53 activation. Furthermore, we 
observed a significant reduction in the expression of the p53 transcriptional 
target p21 (Figure 14D). These results demonstrated that in ZNF668-knockdown 
cells, the overall activation status of p53 and p53 downstream response after 
DNA damage is impaired. 
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Figure 14. ZNF668 regulates both the maintenance and stress-induced 
stabilization of p53. (A) U2OS cells, (B) MCF10A cells and (C) MCF7 were 
transfected with siRNAs targeting ZNF668, and the knockdown cells were 
treated with UV radiation (50 J/m2) or γ radiation (IR; 10 Gy). Cell lysates were 
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harvested 2 h later and immunoblotted with antibodies against the indicated 
molecules. (D) ZNF668 regulates p53-downstream p21 expression. U2OS cells 
were transfected with siRNAs targeting ZNF668, and the knockdown cells were 
treated with γ radiation (IR; 10 Gy). Cell lysates were harvested 24 h later and 
immunoblotted with antibodies against the indicated molecules. 
 
 
 
 Since ZNF668 has been shown to be mutated in breast cancer, we next 
tested whether ZNF668 with mutations found in patient samples has the effect of 
ZNF668 on p53 activity. FLAG-tagged ZNF668 vectors that harbored mutations 
found in patient tumor samples were constructed through site-directed 
mutagenesis and expressed in U2OS cells. Importantly, we found that mutant 
ZNF668 could not stabilize p53 as efficiently as wild-type ZNF668 (Figure 15A). 
We also tested whether wild-type and mutant ZNF668 were similar in terms of 
regulating p53-dependent transcriptional activity. Analysis of p53 function using 
a p53-luciferase reporter showed that the ability of ZNF668 mutants to activate 
p53 was impaired compared to that of wild-type ZNF668 (Figure 15B). These 
results indicated that ZNF668 mutations in patients may lead to impaired p53 
activation, similarly to how p53 mutations can lead to impaired p53 activation. 
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Figure 15. Mutant ZNF668 did not stabilize p53 as much as did wild-type 
ZNF668. (A) U2OS cells were transfected with wild-type or mutant Flag-tagged 
ZNF668. Forty-eight hours later, cell lysates were harvested and immunoblotted 
with antibodies against the indicated molecules. (B) Luciferase assay in U2OS 
cells transfected as indicated. Results represent the mean ± SD of three 
experiments. 
 
 
3.4   ZNF668 facilitates p53 stabilization by disrupting MDM2-mediated 
ubiquitination and degradation 
To determine whether ZNF668 regulates p53 protein stability through the 
MDM2-mediated proteasome pathway, we first tested whether ZNF668 could 
counteract the effect of MDM2 on p53. p53, MDM2, and ZNF668 were 
coexpressed in U2OS cells. MDM2 significantly decreased the p53 protein level, 
which could be restored, at least in part, by simultaneous expression of ZNF668 
(Figure 16). 
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Figure 16. ZNF668 partially restores p53 protein level when ZNF668 is co-
expressed with MDM2. U2OS cells were transfected with p53 (0.05 μg), MDM2 
(1 μg), and ZNF668 (0~1 μg). Cell lysates were harvested 48 h later and 
immunoblotted with antibodies against the indicated molecules. 
 
 
 
 
 
 To test whether ZNF668 affects the interaction between MDM2 and p53, 
we performed an in vitro binding assay. Purified GST-ZNF668, MDM2, and p53 
proteins were mixed and pulled down with MDM2 antibody. We found that 
addition of purified ZNF668 protein decreased MDM2-p53 binding in a dose-
dependent manner (Figure 17). These data indicated that ZNF668 disrupts the 
interaction between MDM2 and p53. 
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Figure 17. The presence of ZNF668 decreases the interaction between MDM2 
and p53. Purified MDM2 and p53 were mixed in in vitro binding buffer, and GST-
ZNF668 was added into the reaction at different GST-ZNF668:MDM2 ratios (0:1, 
2:1, 4:1, and 8:1). Two hours later, the protein complex was immunoprecipitated 
with MDM2 antibody and immunoblotted with antibodies against the indicated 
molecules. 
 
 
 The presence of nutlin, which inhibits MDM2-p53 interaction, stabilizes 
and activates p53 (Vassilev et al., 2004; Colaluca et al., 2008). We found that 
nutlin treatment of ZNF668-knockdown cells reversed the effect of ZNF668 
knockdown on DNA damage-induced p53 activation (Figure 18). These results 
further supported the MDM2-p53 interaction as the key target of by which 
ZNF668 induces p53 stabilization. 
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Figure 18. Nutlin restores ZNF668 knockdown effects on p53 response to DNA 
damage. U2OS cells were transfected with siRNA duplexes targeting ZNF668, 
and the ZNF668-knockdown cells were pretreated with or without nutlin. Two 
hours later, cells were treated with UV radiation (50 J/m2) or γ radiation (IR; 10 
Gy). Cell lysates were harvested 2 h later and immunoblotted with antibodies 
against the indicated molecules.  
 
 
 
3.5      MDM2 regulates p53 protein turnover through its E3 activity 
To test whether ZNF668 blocks MDM2-mediated p53 ubiquitination and 
degradation, cells were treated with the proteasome inhibitor MG132. As 
expected, MG132 treatment abolished the effect of ZNF668 on p53 level (Figure 
19A, left). Moreover, we detected decreased ubiquitination of p53 when ZNF668 
was overexpressed (Figure 19A, right), suggesting a role of ZNF668 in 
counteracting MDM2-mediated p53-ubiquitination. Interestingly, we also found 
that ZNF668 facilitated MDM2 autoubiquitination (Figure 19B). This observation 
was consistent with previous findings that L11 differentially regulates MDM2 and 
p53 ubiquitination (Dai et al., 2006). We speculate that in addition to directly 
blocking MDM2-p53 interaction (Figure 17), ZNF668 might also alter MDM2’s 
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function by inducing autoubiquitination of MDM2 molecules. The dysregulated 
ubiquitination of MDM2 might further facilitate the stabilization of p53 by altering 
MDM2 E3 ligase activity or MDM2’s binding affinity for its substrates. 
 
 
Figure 19. ZNF668 affects p53 and MDM2 ubiquitination. (A) ZNF668 decreases 
endogenous p53 ubiquitination. U2OS cells were transfected with Flag-ZNF668 
and treated with or without 10 μM MG132 for 6 h. Cell lysates were harvested 
and analyzed. p53 levels were normalized by loading proportionally different 
amounts of cell extracts. Cell lysates were immunoprecipitated with p53 antibody 
and immunoblotted as indicated. (B) ZNF668 increases endogenous MDM2 
ubiquitination. U2OS cells were transfected with Flag-ZNF668 and treated with 
or without 10 μM MG132 for 6 h. Cell lysates were harvested and analyzed. Cell 
lysates were immunoprecipitated with MDM2 antibody and immunoblotted as 
indicated. 
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3.6      ZNF668 suppresses tumorigenicity of human breast cancer cells 
Since we found that ZNF668 regulates the stability of p53 protein, we 
posited that ZNF668 might itself function as a tumor suppressor gene. To test 
this possibility, we first examined the proliferation of cells ectopically expressing 
ZNF668. Overexpression of ZNF668 repressed proliferation of MCF7 cells 
(Figure 20A) and their ability to grow in soft agar (Figure 20B). In contrast, 
knockdown of ZNF668 increased soft agar colony formation in nontumorigenic 
MCF10A cells (Figure 20B). 
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Figure 20. ZNF668 suppresses proliferation and transformation of human breast 
cancer cells. (A) Expression of ZNF668 reduces the proliferation of MCF7 cells. 
Control or ZNF668-overexpressing MCF7 cells were seeded in a 96-well plate at 
5×103 cells per well. Cell proliferation was measured by MTT assay for 4 days. 
Results represent the mean ± SD of three independent experiments. (B) 
Expression of ZNF668 reduces the cell transformation of MCF7 cells. 
Knockdown of ZNF668 increases the transformation of MCF10A cells. ZNF668-
expressing MCF7 cells or ZNF668-knockdown MCF10A cells were seeded in 
0.35% agarose gel at 1×104 or 5×103 cells per plate. Viable colonies of MCF7 or 
MCF10A clones in three plates were counted; all soft agar assays were 
performed in triplicate. Results represent the mean ± SD of three independent 
experiments. 
 
 
 
 
 Given that ZNF668 effectively suppressed in vitro cellular transformation, 
we next tested whether ZNF668 suppressed tumorigenicity in vivo. Mice were 
injected in the mammary glands with ZNF668-overexpressing or vector-control 
MCF7 cells and monitored weekly for tumor formation. By week 8, all 10 mice 
injected with ZNF668-overexpressing clones remained tumor free, whereas all 
five of the control mice had developed tumors (Figure 21), indicating the ability 
of ZNF668 to suppress tumorigenicity in vivo. 
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Figure 21. ZNF668 suppresses tumor growth. ZNF668-overexpressing or vector-
control MCF7 cells were injected into the mammary glands of nude mice (5×106 
cells per mouse), and tumor volumes were measured every 2 days. Results 
represent the mean ± SD of three independent experiments. 
 
 
3.7  ZNF668 suppresses tumorigenicity in both p53-dependent and 
independent-manners 
To determine whether p53 is the only target mediating ZNF668’s activity 
in suppressing cellular transformation, we also performed in vitro cell 
proliferation and transformation assays using MCF7-p53-knockdown cells. Both 
MCF7-control and MCF7-p53-knockdown cells were transfected with FLAG-
tagged ZNF668, and cells were selected with G418 for 10 days. Overexpression 
of ZNF668 was confirmed by Western blotting analysis (Figure 22A). ZNF668 
suppressed the proliferation and transformation phenotype (Figure 22B and C) 
of MCF7-p53-knockdown cells, but to a lesser extent than it suppressed the 
proliferation and transformation phenotype of MCF7-control cells, indicating that 
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ZNF668 could suppress cell transformation through both p53-dependent and 
p53-independent pathways. 
 
 
Figure 22. ZNF668 suppresses transformation phenotype of human breast 
cancer cells partially through p53. (A) Expression of Flag-ZNF668 in MCF7 
control and MCF7-p53-knockdown (KD) cells. Cells were transfected with Flag-
ZNF668. Two days later, cells were split and selected with G418 for another 10 
days. Cell lysates were harvested and immunoblotted with antibodies against 
the indicated molecules. (B) Expression of ZNF668 reduces the proliferation of 
both MCF7 control and MCF7-p53-knockdown cells. Cells were transfected with 
Flag-ZNF668 and seeded in a 96-well plate at 5×103 cells per well. Cell 
proliferation was measured by MTT assay for 4 days. The growth rates of cells 
were calculated. Results represent the mean ± SD of three independent 
experiments. (C) ZNF668 suppresses cell transformation in both MCF7 control 
and MCF7-p53-knockdown cells. Cells were transfected with Flag-ZNF668 and 
seeded in 0.35% agarose gel at 5×103 cells per plate. Left: viable colonies in 
three plates were counted. Right: the colony formation rate was calculated; all 
soft agar assays were performed in triplicate. Results represent the mean ± SD 
of three independent experiments. Student’s t-test. 
 
 43
3.8      Discussion 
Our findings identify ZNF668 as a novel nucleolar protein that interacts 
with known nucleolar proteins NPM and NS. Recent studies have shown that the 
function of nucleolar proteins is not limited to participating in ribosomal 
biogenesis. Indeed, the nucleolus appears to be the site for convergence of the 
p53 pathway through regulation of different nucleolar proteins under various 
types of cellular stress (Kamijo et al., 1998; Colombo et al., 2002; Tsai and 
McKay 2002; Lohrum et al., 2003; Dai et al., 2006). Thus, the nucleolar 
localization of ZNF668 and its interaction with known nucleolar proteins 
suggested a potential role of ZNF668 in p53 regulation. 
 By forward and reverse genetic approaches, we clearly demonstrated a 
critical role of ZNF668 in p53 protein stabilization through inhibition of the p53 
negative regulator, MDM2. Our findings further suggest that ZNF668 regulates 
MDM2 through a direct interaction between ZNF668 and MDM2-p53 complex 
since ZNF668 interacted with MDM2 and p53 in vivo and in vitro and since 
ZNF668 interfered with the MDM2-p53 interaction. It has been shown that 
physical interaction between MDM2 and p53 is a prerequisite for MDM2 to 
ubiquitinate p53 (Haupt et al., 1997; Kubbutat et al., 1997; Michael and Oren 
2003). Therefore, our results strongly support alterations in direct protein-protein 
interactions as a mechanism by which ZNF668 regulates p53 and MDM2-
mediated p53 ubiquitination in vivo. Our findings do not, however, exclude the 
possibility that ZNF668 could also regulate p53 through other pathways. For 
example, p53 can be regulated at the posttranslational level through 
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modifications such as phosphorylation and acetylation. ZNF668 could serve as a 
platform for assembly of complexes needed for p53 posttranslational 
modifications in response to cellular stress and thereby promote p53 activation 
and stabilization. Future experiments will be needed to determine whether other 
mechanisms besides direct protein-protein interactions may also be involved in 
ZNF668-mediated p53 regulation. 
 Recent reports indicate that the central acidic domain of MDM2 is 
important for controlling p53 activity (Ma et al., 2006; Wallace et al., 2006). 
Indeed, this domain was previously shown to be required for p53 ubiquitination 
and degradation (Argentini et al., 2001; Meulmeester et al., 2003). We found in 
the current study that deletion of residues 212-296 of MDM2 attenuated the 
interaction between ZNF668 and MDM2, indicating a mechanism by which 
ZNF668 could attenuate MDM2-mediated ubiquitination and degradation of p53. 
Indeed, it has previously been suggested that the ubiquitination of p53 is a 
stepwise process accompanied by a conformational alteration (Gu et al., 2001). 
Therefore, it is possible that binding of ZNF668 to the central domain of MDM2 
induces a conformational change in both MDM2 and p53 that suppresses the 
ubiquitination of p53 but facilitates the autoubiquitination of MDM2 (Figure 23).  
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Figure 23. Schematic model of how ZNF668 interaction with MDM2 protects p53 
from ubiquitin-mediated degradation. p53 is maintained at a low basal level in 
normal cells by MDM2-mediated degradation. When ZNF668 is present, it 
associates with both p53 and MDM2 and prevents MDM2-mediated degradation 
of p53 by disrupting the interaction between MDM2 and p53. The presence of 
ZNF668 leads to an increase of MDM2 auto-ubiquitination and decrease of p53 
ubiquitination, which stabilizes p53. 
 
 
           Balancing MDM2 autoubiquination and ubiquination of its substrates such 
as p53 highly depends on the association between MDM2 with p53 (Stommel 
and Wahl 2004; Ronai 2006). DNA-damage induced phosphorylation of MDM2 
results its dissociation with modified p53 and leads to accelerated MDM2 
autoubiquitination and consequently, p53 stabilization and activation (Stommel 
and Wahl 2004). Our data indicated that ZNF668 could block the interaction 
between MDM2 and p53 (Figure 17), thus facilitated MDM2 autoubiquitination 
and p53 stabilization. Interestingly, it has been shown that L11 and ARF 
(Xirodimas et al., 2001; Brignone et al., 2004; Dai et al., 2006; Ronai 2006) can 
also facilitate autoubiquitination of MDM2 by preventing the recruitment of 
ubiquitinated MDM2 to the proteasome, either through potential adaptor proteins 
or by concealing MDM2 binding sites in the proteasome (Brignone et al., 2004; 
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Ronai 2006), thus inhibiting the postubiquitination pathway. It is therefore 
tempting to speculate that many p53 regulators, such as ARF and ZNF668, 
stabilize p53 protein both by directly interfering with MDM2-p53 interaction and 
by regulating MDM2 posttranslational modifications such as autoubiquitination to 
alter MDM2 E3 ligase activity or binding affinity toward its substrates. 
 Our studies also identified ZNF668 as a potential tumor suppressor in 
breast cancer. ZNF668 was previously identified as a highly mutated gene in 
breast cancer. However, the implications of the mutation of ZNF668 in breast 
cancer development are entirely unknown. Our studies strongly indicate p53 to 
be an important target of ZNF668. Indeed, the two ZNF668 mutants that we 
tested had impaired ability to stabilize p53 further support this notion. Of course, 
we cannot rule out impacts of ZNF668 on proteins other than p53. Indeed, the 
fact that ZNF668 also suppressed cell transformation in p53-mutated cells 
(Figure 22), albeit to a lesser degree than in cells with wild-type p53, indicates 
that ZNF668 can suppress cell transformation through both p53-dependent and 
p53-independent pathways. In future studies, we will identify the p53-
independent ZNF668 targets and dissect the function of ZNF668 in both p53-
dependent and p53-independent pathways. 
 
 
 
 
 
 47
PART II.  ROLE OF ZNF668 IN DNA REPAIR AND CHROMATIN 
REMODELING 
 
CHAPTER 4 INTRODUCTION 
 
4.1      Tumor suppressor and DNA repair 
Tumor suppressor genes have diverse functions. The role of tumor 
suppressors in DNA damage response is well established. Many tumor 
suppressors, such as ATM, BRCA1, BRCA2, NBS1, CHK2 and p53, are 
involved in different steps of DNA damage response pathway, which leads to 
checkpoint response, increased DNA repair or cell apoptosis (Liang et al., 2009). 
Loss of the function of tumor suppressors leads to genetic instability, deficient 
DNA repair or impaired damaged cell death and results in tumor formation. For 
example, the tumor suppressor genes BRCA1 and BRCA2 play roles in DNA 
damage repair (Venkitaraman et al., 2001). BRCA2 belongs to the tumor 
suppressor gene family and the protein encoded by this gene is involved in the 
repair of chromasomal damage with an important role in HR repair of DNA 
double strand breaks (Venkitaraman et al., 2001). Understanding the role of 
tumor suppressors in DNA damage response pathway provides an alternative 
opportunity for improving disease detection and management. 
 
4.2      DNA damage response pathways 
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Cellular DNA is continuously exposed to various DNA damage signals 
(Hoeijmakers et al., 2009). Endogenous signals including spontaneous DNA 
alterations during replication, reactive oxygen species generated by cellular 
metabolism activity and intercross between DNA bases. Exogenous signals 
such as chemicals, UV radiation and ionizing radiation can cause different types 
of DNA lesions.  
DNA damage response is a highly conserved but complicated process 
with multiple steps including the initial recognition and signaling of DNA lesions, 
the access of repair proteins to the damaged DNA and the restoration of the 
chromatin to its original state (Harper et al., 2007; Rouse et al., 2002). Although 
there are different types of DNA repair in response to different classes of DNA 
lesions, DNA damage responses usually occur by a common general process 
(Figure 24). Right after the DNA damage, DNA damage sensors detect the 
damage and recruit transducer kinases such as ATM/ATR/DNA-PK and 
mediators such as MDC1 to the damage sites. The kinases will activate 
downstream effectors with the coordination of mediators. Mediators mediate the 
signal from the transducer kinases to the effectors. Effectors execute the DNA 
damage response, which includes activation of cell cycle checkpoints, repair of 
the damage, transcriptional regulation and activation of apoptosis if the damage 
is too severe to be repaired (Bartkova, 2007). 
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Figure 24. A common model for the DNA damage response. The presence of a 
lesion in the DNA, which can lead to replication stalling, is recognized by various 
sensor proteins. These sensors initiate signaling pathways that have an impact 
on a wide variety of cellular processes. (Stephen P. Jackson & Jiri Bartek, 2009) 
 
 
4.3     DNA repair pathways 
To preserve its genomic integrity, cells need to develop different types of 
repair pathways to fix the various types of DNA damage. For example, base-
excision repair (BER) is important for the repair of DNA alterations caused by 
chemicals (Jiricny et al.,2006); mismatch repair (MMR) can replace the 
misrepaired DNA bases with correct bases; nucleotide excision repair (NER) 
repairs more complex lesions, such as pyrimidine dimers and intrastrand 
crosslinks; single-strand break repair (SSBR) repairs single strand breaks 
caused by UV irradiation; double strand breaks (DSBs) are mainly repaired by 
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homologous recombination (HR) and nonhomologous endjoining (NHEJ) 
(Caldecott, 2008; West, 2003).  
For DNA double strand breaks, HR uses the undamaged sister 
chromatids as template to accurately restore the break. In contrast, NHEJ 
repairs the break by direct ligation of the two broken ends, which can result in 
inaccurate relegation of the breaks and cause DNA deletions. Cells activate 
different repair pathway in co-ordinance with specific cell cycle phase (Figure 
25) (Branzei et al., 2008; Mandal et al., 2010).  
 
 
Figure 25. DNA double strand break repair during cell cycle. In G1, double 
strand breaks are recognized by the KU dimer to provide a scaffold and recruit 
the repair proteins to perform NHEJ repair. In S and G2 cells, DNA lesions are 
detected and processed by the MRE11–RAD50–NBS1 (MRN) complex. This 
leads to recruitment and activation of ataxia-telangiectasia mutated (ATM) 
signalling pathway and leads to transient cell cycle arrest for DNA repair. 
Replication blocks during S phase activate ataxia-telangiectasia- and RAD3-
related (ATR) activation and lead to cell cycle arrest (Mandal et al., 2010). HR 
repair is the major repair pathway during G2/S phase. 
 
4.4     Chromatin dynamics and gene regulation 
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In eukaryotic cells, genomic DNA is packed with histones to form the 
nucleosomes, which are further packaged into a condensed chromatin structure. 
Nucleosomes are comprised of 147 bp of DNA wrapped around a hetero-
octamer of histones H2A, H2B, H3, and H4 (Khorasanizadeh, 2004). Generally, 
the condensed chromatin structure will suppress cellular processes that involve 
DNA transactions such as DNA replication, gene transcription and DNA double 
strand break repair (Felsenfeld et al., 2003). 
Gene transcription initiation involves the opening of chromatin structure at 
the promoter region to allow access for transcription factors to bind DNA 
sequences (Wollffe 1998). In order to overcome the chromatin barrier, cells 
have developed several pathways to relax the chromatin structure. The ATP-
dependent chromatin remodeling complexes utilize the energy from ATP 
hydrolysis to displace nucleosomes and induce conformational changes in 
chromatin (Lusser et al., 2002; Peterson et al., 2002; Flaus et al., 2004). The 
posttranslational modifications of the core histones, such as phosphorylation, 
methylation, ubiquitination and acetylation (Jenuwein et al., 2001; Turner, 2002; 
Kouzarides et al., 2007) have emerged as another important mechanism by 
which cells regulate the structure and accessibility of chromatin. Moreover, cells 
alter the composition of nucleosomes through the incorporation of histone 
variants that can directly or indirectly alter the accessibility of DNA within 
chromatin (Kamakaka et al., 2005; Henikoff et al., 2005). 
 
4.5      Chromatin dynamics and DNA repair  
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The chromatin structure also has an impact on the DNA damage 
response because in the DNA damage pathway, the condensed chromatin 
structure blocks the DNA repair machinery to access the damaged chromosomal 
DNA lesions.  The chromatin structure is modulated by several mechanisms in 
response to DNA damage. 
ATP-dependent chromatin remodeling complexes regulate the chromatin 
structure in response to DNA damage signal. With the DNA damage signal, 
ATP-dependent chromatin remodelers such as INO80, SWR1 Swi2-family 
proteins and SWI/SNF chromatin remodeling factors are recruited to the double 
strand breaks (Narlikar et al. 2002; Morrison et al., 2004; van Attikum et al., 
2004; Shim et al., 2005; Chai et al., 2005). These remodelers are responsible for 
efficient initiation of DNA damage response including the induction of histone 
phosphorylation. They are also responsible for the followed histone 
ubiquitination, nucleosome reassemble and the exchange of histones in the 
DNA damage breaks. 
Combinations of the posttranslational modifications in the core histones 
will form so-called “histone code” to regulate different types of cellular process 
such as gene regulation, DNA repair and chromatin condensation (Strahl et al., 
2000). The posttranslational modifications of the core histones can regulate the 
structure and accessibility of chromatin.  The amino- and carboxy-terminal tails 
of histones are the regions that frequently be modified because of their location 
on the chromatin surface. In addition to histone modifications, there are different 
histone variants that consist of different sequence and play different roles from 
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canonical histones. For example, one of the major H2A variants, H2AX differs 
from H2A at various amino acid residues along the entire protein and in its C-
terminal extensions. H2AX is phosphorylated in response to the introduction of 
DNA double-strand breaks, and the phosphorylated H2AX (γ-H2AX) participates 
in foci formation at sites of DNA damage and plays an important role in the 
recognition and signaling of DNA Damage. The phosphorylation of H2AX is 
mediated by ATM/DNA-PK/ATR. ATM and DNA-PK majorly function after 
ionizing radiation (IR), whereas ATR responds to replication stress and UV 
irradiation (Rogakou et al., 1998; Stiff et al., 2004; Czornak et al., 2008; 
Cimprich et al., 2008). Studies have shown that phosphorylated-H2AX (γ-H2AX) 
serves as a platform to recruit and retain DNA repair factors to the DNA damage 
sites without affecting chromatin organization (Celeste et al., 2003). After DNA 
damage, the γ-H2AX is expanded around the double strand break region and 
provides docking sites for other DNA damage and repair proteins such as 
53BP1 and BRCA1.  
The re-open of condensed chromatin structure for efficient DNA repair 
involves induced histone acetylation at the DSB sites. After the incorporation of 
γ-H2AX, other core histones such as H2A, H3 and H4 are modified by 
acetylation and contribute to the destabilization of the nucleosome and the 
opening of chromatin. Other histone modifications such as ubiquitylation and 
sumoylation also have roles in histone exchange and the recruitment of the 
chromatin remodeling complexes (Attikum et al., 2009). 
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After repair has been completed, γ-H2AX is eliminated from the chromatin 
surrounding the repaired DSB, by either replacement with H2AZ variant 
(Mizuguchi et al., 2004) or dephosphorylation by phosphatases such as hPP2A, 
hPP4C, hPP6 and hWip1 (Chowdhury et al., 2005; Chowdhury et al., 2008; 
Macurek et al., 2010; Douglas et al., 2010).  
 
4.6      Histone acetylation and its role in transcription regulation 
Among all the posttranslational modifications of histones, histone 
acetylation by histone acetyltransferase (HAT) complexes has been implicated 
in both transcriptional regulation and DNA damage repair. 
HAT can catalyze the transfer of an acetyl group from acetyl-CoA to the 
lysine amino groups on the N-terminal tails of histones. In actively transcribed 
regions of chromatin histones tend to be hyperacetylated, whereas in 
transcriptionally silent regions histones are hypoacetylated. Histone acetylation 
can neutralize histone charge and weaken DNA-histone interaction. The acetyl-
lysines on histone tails can provide recognition sites for transcription factors 
involved in either the activation or repression of gene expression. For example, 
lysine acetylation provides a stable epigenetic mark on chromatin for SWI/SNF 
and RSC chromatin remodeling complex or HAT complexes to dock and in turn 
regulate gene expression (Hassan et al., 2002). 
In addition, other covalent modification of histones, which is called as 
histone code, will provide an epigenetic marker for gene expression (Strahl et 
al., 2000). The complexity of the histone code also influences recruitment of 
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HAT to promoters. For example, phosphorylation of histone H3 serine 10 can 
enhance the targeting of Gcn5 HAT to the INO1 promoter in yeast (Lo et al., 
2001). In mammals, methylation of H3 lysine 9 inhibits HAT targeting and 
promoter acetylation (Rea et al., 2000). All of these histone modifications will 
coordinately provide a unique signal for specific gene activation or suppression. 
 
4.7      Histone acetylation and DNA repair 
Recent studies have implicated the role of chromatin acetylation by HAT 
complexes in DNA-damage detection and DNA repair (Ikura et al., 2000; 
Carrozza et al., 2003; Murr et al., 2006). For example, Tip60 is one of the HATs 
that acetylate H2A and its variant H2AX on lysine 5 (K5). In drosophila, Tip60’s 
activity on H2Av acetylation is important for histone variant H2AZ exchange with 
phosphorylated-H2AX, which is important for DNA repair (Kusch et al., 2004). 
Acetylation of H2AX (Kusch et al., 2004; Downs et al., 2004) and histone H4 
(Murr et al,. 2006; Bird et al., 2002; Downs et al., 2004) is required for the 
formation of open chromatin structures at DSBs and is critical for the access of 
the DNA repair machinery to DSBs (Murr et al., 2006; Bird et al., 2002; Kusch et 
al., 2004; Jha et al., 2008). Recent studies also showed that H3 acetylation on 
lysine 56 (K56) is required for the appropriate nucleosome assembly and 
facilitates DNA double strand break repair (Li et al., 2008; Chen et al., 2008). 
Therefore, the increased acetylation of histones at DNA lesions after DNA 
damage can contribute to DNA double strand break repair by regulating histone 
variant exchange, remodeling chromatin structure and recruiting DNA repair 
proteins to the sites of DNA damage. However, the precise underlying 
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mechanism mediating enzymes responsible for the histone modifications and 
their recruitment to DNA lesions remains poorly understood.  
 
4.8      Hypothesis and project goals 
ZNF668 (zinc finger protein 668) was initially identified and validated as a 
highly mutated gene in breast cancer (Sjoblom et al., 2006). Our preliminary 
data showed that ZNF668 functions as a potential tumor suppressor and it is 
involved in p53 regulation. Since tumor suppressors play an important role in 
DNA damage response, we hypothesize that, as a novel tumor suppressor and 
a key regulator of p53, ZNF668 might participate in DNA damage response. 
In this part of the study, we aim to demonstrate the functional interaction 
among ZNF668, histones, and chromatin. We study the role of ZNF668 as a 
novel tumor suppressor gene in regulation of histone acetylation and chromatin 
structure after DNA damage and reveal its mechanistic function in regulating 
DNA damage repair.  
 
CHAPTER 5 MATERIALS AND METHODS 
 
5.1     Cell Culture and Transfection 
U2OS cells were purchased from the American Type Culture Collection. 
U2OS cells were maintained in McCoy's 5A medium (Cellgro) supplemented 
with 10% fetal bovine serum (FBS) with glutamine, penicillin, and streptomycin. 
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Cells were incubated at 37°C in a humidified incubator with 5% CO2 and 
transfected with Fugene 6 (Roche), or Oligofectamine (Invitrogen). 
 
5.2     Plasmids and small interfering RNAs (siRNAs) 
To generate FLAG-ZNF668, full-length ZNF668 cDNA was amplified by 
polymerase chain reaction (PCR) and subcloned into pCMV5-3 x FLAG vector 
(Sigma). The siRNA-resistant ZNF668 was created from 3 x FLAG-ZNF668 
using the QuickChange II Site-Directed Mutagenesis Kit (Stratagene). FLAG-
H2AX plasmid was a gift from Dr. Jiri Lukas. ZNF668 knockdown was achieved 
by RNA interference using siRNA (Dharmacon). The ON-TARGETplus ZNF668 
siRNA duplex and ON-TARGETplus SMARTpool ZNF668 siRNA mix were 
purchased from Dharmacon Research, Inc. ON-TARGETplus nontargeting 
siRNA was used as a control for the siRNA reactions. RNA duplexes or 
SMARTpool (final concentration 100 nM) were transfected into the U2OS cells 
using Oligofectmine according to the manufacturer’s protocol (Invitrogen). Cells 
transfected with ZNF668 siRNA were incubated for 2 or 3 days. A decrease in 
the respective protein levels was verified by Western blotting.  
 
5.3     Antibodies and Reagents 
Rabbit polyclonal anti-ZNF668 antibody (Proteintech Group, Inc.) was 
generated as described in Chapter 2.3. Anti-FLAG M2-agarose affinity gel was 
purchased from Sigma. RPA antibody was purchased from NeoMarkers. 
Phospho-RPA32 (S4/S8) antibody was purchased from Bethyl. Rad51 was 
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purchased from Calbiochem, ATM, phospho-H2AX were purchased from Cell 
Signaling. Histone H2A (acetyl K5) antibody was from Abcam. Anti-Tip60 and 
phospho-ATM were purchased from Millipore. Fluorochrome-conjugated 
secondary antibodies were purchased from Jackson ImmunoResearch 
Laboratories. Cisplatin was purchased from Sigma. Sodium butyrate and 
trichostatin were obtained from Sigma and used at 5 mM or 200 ng/mL 
respectively.  
 
5.4     Affinity purification of ZNF668 and H2AX protein complex 
U2OS cells were transiently transfected with empty FLAG plasmid, FLAG-
ZNF668 or FLAG-H2AX plasmid. Forty-eight hours later, whole cellular extracts 
were prepared with RIPA buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 10% 
sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl 
fluoride, 1 mM sodium orthovanadate, and 1 mM NaF) and immunoprecipitated 
with anti-FLAG M2 affinity gel (Sigma) overnight. Bead-bound 
immunocomplexes were eluted with 3XFLAG peptide (Sigma). 
Immunocomplexes were separated by 7% or 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Protran 
nitrocellulose membrane (Fisher Scientific). Membranes were blocked in Tris-
buffered saline-0.1% Tween 20 (TBS-T)/5% (w/v) milk for 1 h at room 
temperature and were then incubated with primary antibodies diluted in TBS-
T/5% (w/v) milk for 2 h at room temperature or overnight at 4°C. Subsequently, 
membranes were washed with TBS-T and incubated with horseradish 
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peroxidase secondary antibody (1:5000) (Jackson ImmunoResearch) diluted in 
TBS-T/5% skim milk. Membranes were washed in TBS-T, and bound antibody 
was detected by enhanced chemiluminescence (GE Healthcare). 
 
5.5     Immunofluorescent Microscopy 
For detection of DNA damage induced foci of p-RPA34, RPA34 and 
Rad51, cells were treated with cytoskeleton and stripping buffer, fixed with 4% 
paraformaldehyde and then permeabilized with 0.5% NP-40 and 1% Triton X-
100. The primary antibodies were as follows: mouse anti-RPA (1:1000), rabbit 
anti-pRPA (1:1000) and rabbit anti-Rad51 (1:500). Primary antibodies were 
incubated for 2h at room temperature (RT) and secondary antibodies donkey 
anti-rabbit conjugated Alexa 594 and goat anti-rabbit conjugated Alexa 488 were 
incubated for 1 h at RT. Slides were mounted in medium containing DAPI 
(Vector laboratories, Burlingame, CA) and analyzed under a fluorescence 
microscope. The number of foci per cell was scored for at least 50 cells per 
sample. For chromatin remodeling, cells were incubated in the presence of 
sodium butyrate (5 mM) after ultraviolet (UV) or ionized radiation (IR) exposure 
before staining for DNA damage foci was performed.   
 
5.6      Immunoblotting, chromatin fractionation and Immunoprecipitation 
Cells were washed in phosphate-buffered saline and lysed in urea buffer 
or modified RIPA buffer. For chromatin fractionation, cells were lysed in (10 mM 
HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.34 M sucrose, 10% Glycerol, 1 
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mM dithiothreitol, and 0.1% Tirton X-100), and nuclear extracts were lysed in 
buffer (3 mM EDTA, 0.2 mM EGTA and 1 mM dithiothreitol). After clarification, 
cell pellets were resuspended in SDS sample buffer. For immunoprecipitation, 
cells were lysed in RIPA buffer. After clarification, cell lyses were 
immunoprecipitated with specific antibodies (RPA or ZNF668). The 
immunocomplexes were collected on Protein A/G plus-conjugated agarose 
beads (Santa Cruz Biotechnology). Cellular lysates or immunocomplexes were 
subjected to SDS-PAGE analysis. 
 
5.7     Cell survival and proliferation assays  
U2OS cells were transfected with ZNF668 siRNAs and 72 h after the 
transfection, cells were plated at low density and irradiated with UV or IR. Cells 
were incubated for 2–3 weeks to allow colonies to form. Colonies were detected 
by staining with 2% methylene blue/50% ethanol. Colonies containing 50 or 
more cells were counted. For proliferation assay, cells transfected with ZNF668 
siRNAs were seeded in 96 well plates and treated with various doses of 
cisplatin. 72 h after the treatment, MTT assay was performed to measure cell 
viability. 
 
5.8      HR repair analysis 
U2OS cells containing a single copy of the HR repair reporter substrate 
DR-GFP in a random locus were generated as previously described (Peng et al., 
2009). U2OS-DR-GFP cells were transfected with ZNF668 siRNA with or without 
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siRNA-resistant FLAG-ZNF668. 48 hours after transfection, cells were 
transfected with pEGFP-C1 as for transfection efficiency control or pCBASce 
plasmid for detection of HR repair efficiency. 48 hours later, GFP positive cells 
were detected by flow cytometry analysis. Cellquest software (Becton Dickinson, 
San Jose, CA) is used for the acquisition and analysis of FACS data. For 
chromatin remodeling recovery experiments, cells were incubated for 16 hr in 
sodium butyrate (5 mM) or trichostatin (200 ng/mL) to induce chromatin 
remodeling before analysis by flow cytometry. 
 
5.9    PCR analysis of I-SceI-induced DNA cutting 
To assay the cutting efficiency of I-SceI in cells transfected with control or 
ZNF668 siRNA, genomic DNA was extracted at different time points after I-SceI 
transfection and adjusted to equal concentrations. Semi-quantitative PCR was 
carried out using the primers around the DSB site (30 cycles). Beta-actin primers 
(Applied biosystems) were used as an internal control (25 cycles).  
 
5.10    Cell cycle analysis 
Cells from HR repair analysis were fixed in 70% cold ethanol (-20°C) 
overnight. After washing with cold phosphate-buffered saline (PBS), cells were 
incubated in staining solution (40 μg/mL propidium iodide, 50 μg/mL RNAase A 
and 0.05% Triton X-100). Cell cycle analysis was performed at the M. D. 
Anderson Cancer Center Flow Cytometry Facility.  
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CHAPTER 6 FUNCTION OF ZNF668 IN DNA REPAIR, HISTONE 
ACETYLATION AND CHROMATIN STRUCTURE REGULATION 
 
6.1      ZNF668 depletion causes prolonged DNA damage after IR. 
To understand the role of ZNF668 in DNA damage response, we first 
measured cell survival following treatment with DNA damage agents. ZNF668 
deficient cells showed an increased sensitivity to ionize irradiation and UV light 
by clonogenic survival assays (Figure 26A). In a cell proliferation assay, ZNF668 
knockdown cells were also sensitive to DNA cross-linking agent cisplatin in a 
dose dependent manner (Figure 26B). These data indicate ZNF668 depletion 
cells are sensitive to DNA damage. Therefore, ZNF668 is needed for cell 
survival in response to a wide variety of DNA damaging agents.  
 
 
Figure 26. ZNF668 depletion impairs cell survival after DNA damage. (A) 
ZNF668-depletion impaired cell survival in U2OS cells exposed to UV or IR 
radiation. Control or ZNF668-depletion U2OS cells were seeded at low density 
and treated with UV or IR. Viable cell colonies in three plates were counted. The 
graphs represent the mean ± SD of three independent experiments. (B) 
ZNF668-depletion impaired cell proliferation in cells exposed to DNA damage 
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reagent (cisplatin). Control or ZNF668-depletion U2OS cells were seeded in a 
96-well plate at 2×103 cells per well and treated with various doses of cisplatin. 
Cell proliferation was measured by MTT assay after 3 days. Results represent 
the mean ± SD of three independent experiments.  
 
6.2     ZNF668 affects DNA damage repair. 
Effective DNA repair of damaged DNA is essential to cell survival. To test 
whether ZNF668 plays a role in DNA repair, we measured DNA repair efficiency 
in ZNF668 knockdown cells using the neutral comet assay that specifically 
measures double-strand breaks (DSB). Although induction of DNA breaks was 
similar in ZNF668-containing and ZNF668-deficient cells, ZNF668-deficient cells 
exhibited a lower repair efficiency compared to control, thereby indicating that 
ZNF668 depletion compromised the repair of DNA breaks (Figure 27). 
 
Figure 27. ZNF668-depletion impaires DNA repair. Comet analyses at the 
indicated time points after exposure of U2OS cells transfected with control 
siRNA, ZNF668 siRNA #1 or ZNF668 siRNA #2 to ionizing radiation (IR). (Left) 
Representative images. (Right) Quantitative analysis of three independent 
experiments and representative western blot analyses showing the knockdown 
of ZNF668. Percentage of cells with damaged DNA (tail moment greater than 1) 
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in control cells without IR exposure was set as 1. At least 100 cells were scored 
in each sample and each value represents the mean ± SD of three independent 
experiments; Student t-test. 
 
6.3     ZNF668 affects HR repair of DNA double strand breaks. 
In mammalian cells, homologous recombination (HR) is one of major 
conserved pathways involved in DSB repair. To confirm ZNF668’s role in DSB 
repair, we analyzed ZNF668-deficient cells using an HR repair analysis system. 
In this system, DSB was generated by the introduction of I-SceI enzyme and the 
HR repair efficiency was reflected by the induced-GFP+ signal. We found 
ZNF668 knockdown cells showed a significant decrease (30%) in HR repair 
induced-GFP+ cells, indicating defective HR repair (Figure 28A). To rule out the 
possibility that ZNF668 status may affect the access of I-SceI to chromatin DNA, 
we detected I-SceI-induced cutting efficiency by semi-quantitative PCR analysis 
over a time course by using a primer pair to amplify only the uncut I-SceI locus. 
The I-SceI cutting efficiency was similar in ZNF668-containing and ZNF668-
deficient cells (Figure 28B).  
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Figure 28. Impaired HR results from the loss of ZNF668. (A) ZNF668-depletion 
impaired HR repair. ZNF668-depleted cells transfected with ZNF668 siRNA #1 
and siRNA smartpool were subjected to HR repair analysis. Each value is 
relative to the percentage of GFP+ cells in I-SceI-transfected cells with control 
siRNA transfection, which was set to 1 and represents the mean ± SD of three 
independent experiments; Student’s t-test. (B) Cutting efficiency of I-SceI was 
detected by semi-quantitative PCR using a primer pair flanking the DSB site. 
ZNF668 knockdown cells exhibited no differences in PCR products when 
compared to control cells at different time points, suggesting similar cutting 
efficiency of I-SceI in ZNF668 knockdown and control cells.  
 
 
Furthermore, ZNF668-deficient and ZNF668-containing cells showed 
similar cell-cycle profiles (Figure 29A), indicating that loss of ZNF668 didn’t alter 
cell-cycle position during I-SceI cleavage. Moreover, transfection of ZNF668-
containing and ZNF668-deficient cells with a control GFP-expressing vector 
(pEGFP-C1) resulted in similar numbers of GFP-positive cells (Figure 29B), 
indicating that the lower frequency of repaired GFP+ cells in ZNF668-deficient 
cells was not due to a lower transfection efficiency. 
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Figure 29. Cell cycle profiles and transfection efficiency of ZNF668-depletion 
cells with I-SceI transfection. (A) Cell cycle profiles of cells that were analyzed 
for HR repair efficiency. ZNF668 knockdown didn’t affect cell cycle distribution. 
(B) Transfection efficiency was monitored by using a control GFP-expression 
vector (pEGFP-C1) in indicated cells. ZNF668 knockdown and control cells 
showed similar transfection efficiency (~40%). 
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To further test whether the defective HR repair in ZNF668 knockdown 
cells is specific due to the lack of ZNF668, ectopic siRNA-resistant FLAG-
ZNF668 was introduced back to the ZNF668-depleted cells and it was able to 
restore the HR repair efficiency (Figure 30). All together, our data reveal a 
critical function of ZNF668 in HR repair.  
 
 
 
 
Figure 30. siRNA resistant Flag-ZNF668 restores the defective HR repair in 
ZNF668-depleted cells. Each value is relative to the percentage of GFP+ cells in 
I-SceI-transfected cells with control siRNA transfection, which was set to 1 and 
represents the mean ± SD of three independent experiments. Western blotting 
analyses to demonstrate the effective ZNF668 knockdown and Flag-ZNF668 
overexpression were shown next to the graph.  
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6.4    ZNF668 doesn’t affect ATM/ATR DNA damage detection and 
signaling. 
To test whether DNA-damage detection and signaling is affected in cells 
lacking ZNF668, we investigated the ATM and ATR signaling pathway after IR or 
UV irradiation treatment. Treatment with IR induced ATM and Chk2 
posphorylation at similar levels in ZNF668-containing and ZNF668-defecient 
cells (Figure 31A and B).  
 
 
 
Figure 31. ZNF668-depletion doesn’t affect DNA-damage sensing or signaling. 
(A and B) ZNF668-depletion didn’t affect ATM/Chk2 activation. ZNF668-
containing and ZNF668-depletion U2OS cells were exposed to IR irradiation 
(10Gy) and cell lyses were prepared at the indicated time points after treatment. 
Cell lyses were subjected to Western blot analyses and immunoblotted with 
antibodies against the indicated molecules. (A) ATM phosphorylation and (B) 
Chk2 phosphorylation were analyzed. 
 
 
In parallel, IR induced phosphor-ATM foci were indistinguishable in 
ZNF668-containing and ZNF668-defecient cells (Figure 32A), indicating that 
ATM auto-activation and downstream events occur normally in cells lacking 
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ZNF668. In addition to ATM/Chk2 pathway, UV induced Chk1 phosphorylation 
showed similar levels in both ZNF668-containing and ZNF668-deficient cells 
(Figure 32B).  
 
 
 
Figure 32. ZNF668-depletion doesn’t affect ATM activation and ATR/Chk1 
activation. (A) p-ATM foci formation after DNA damage treatment. ZNF668-
containing and ZNF668-depletion U2OS cells were exposed to irradiation and 
stained with phoshoprylated ATM, counterstained with DAPI. (B) ZNF668-
depletion didn’t affect ATR/Chk1 activation. ZNF668-containing and ZNF668-
depletion U2OS cells were exposed to UV irradiation (50J/m2) and cell lyses 
were prepared at the indicated time points after treatment. Cell lyses were 
subjected to Western blot analyses and immunoblotted with antibodies against 
the indicated molecules. 
 
 
Moreover, the phoshporylation of H2AX was similarly induced in ZNF668-
deficient and ZNF668-containing cells after irradiation (Figure 33). These data 
suggest that the inefficient HR repair in ZNF668-deficient cells is probably not 
caused by the defects in the DNA-damage signaling cascade. 
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Figure 33. Analysis of histone H2AX phosphorylation following DNA damage in 
cells lacking ZNF668. ZNF668-containing and ZNF668-depletion U2OS cells 
were exposed to irradiation and cell lyses were prepared at the indicated time 
points after treatment. Cell lyses were subjected to Western blot analyses and 
immunoblotted with antibodies against the indicated molecules. H2AX 
phosphorylation was analyzed. 
 
 
6.5    ZNF668 affects efficient activation and loading of repair proteins at 
sites of DNA damage.  
Next, we tested whether ZNF668 depletion impair DNA repair proteins 
recruitment to DNA damage site. Replication protein A (RPA) is one of the key 
participants in DSB repair. The RPA phospholylation was significantly decreased 
in ZNF668 deficient cells without affecting the total RPA level (Figure 34A). In 
parallel, the foci formation of p-RPA decreased in ZNF668-deficient cells (Figure 
34B).  
 
 71
 
 
Figure 34. ZNF668 depletion impairs RPA34 phosphorylation. (A) ZNF668 
depletion impairs RPA34 phosphorylation. U2OS cells were transfected with 
siRNAs targeting ZNF668, and the knockdown cells were treated with UV 
radiation (50 J/m2). Cell lysates were harvested 3 h later and immunoblotted with 
antibodies against the indicated molecules. (B) ZNF668 is required for phospho-
RPA34 foci formation. (Left) Representative immunostaining images. Scale bar 
is 10 μM. (Right) The bar graph represents the mean ± SD of three independent 
experiments; Student’s t-test. At least 50 cells were scored in each sample. 
Western blot analyses to demonstrate the effective ZNF668 knockdown were 
shown next to the graph. 
 
We also found that the foci formation of both RPA and Rad51 were 
decreased (Figure 35A and B), indicating ZNF668 contributes to DNA repair 
protein activation and recruitments to DNA damage site to perform repair 
function. 
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Figure 35. ZNF668 depletion impairs DNA repair protein foci formation. (A) 
ZNF668 is required for RPA34 foci formation. (Left) Representative 
immunostaining images. Scale bar is 10 μM. (Right) The bar graph represents 
the mean ± SD of three independent experiments; Student’s t-test. At least 50 
cells were scored in each sample. (B) ZNF668 is required for Rad51 foci 
formation. (Left) Representative immunostaining images. Scale bar is 10 μM. 
(Right) The bar graph represents the mean ± SD of three independent 
experiments; Student’s t-test. At least 50 cells were scored in each sample. 
Western blot analyses to demonstrate the effective ZNF668 knockdown were 
shown next to the graph. 
 
 
6.6      ZNF668 affects association of DNA repair proteins with chromatin. 
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To test whether ZNF668 itself is a chromatin associating protein, 
chromatin fraction was extracted and tested. As shown by Figure 36A, 
endogenous ZNF668 was enriched in chromatin fractionation. Moreover, the 
recruitment of DNA repair proteins to chromatin was also impaired. The 
chromatin binding of p-RPA and RPA were impaired in ZNF668-deficient cells 
(Figure 36B). Interestingly, endogenous ZNF668 associated with RPA34, 
indicating ZNF668 might serve as a platform to recruit DNA repair proteins to 
chromatin (Figure 36C). 
 
Figure 36. ZNF668 depletion impairs association of DNA repair proteins with 
chromatin. (A) ZNF668 is a chromatin association protein. Chromatin 
fractionation was extracted from U2OS cells and cell lysate was subjected to 
Western blot analyses. (Input) total cell lysate in Urea buffer; (Cyto) cytosolic 
fraction; (Non-Chr) Non-chromatin association fraction; (Chr) Chromatin fraction. 
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(B) ZNF668 depletion impaired recruitment of DNA repair proteins to chromatin. 
ZNF668-containing and ZNF668-depletion U2OS cells were exposed to UV or 
IR. The chromatin fraction was prepared at the indicated time post-irradiation 
and subjected to Western blot analyses. (C) Endogenous ZNF668 associates 
with RPA34. Cellular lysates of U2OS cells were prepared by lysing the cells 
with RIPA buffer; immunoprecipitated with anti-ZNF668, anti-RPA34 or 
preimmune IgG; and immunoblotted with antibodies against the indicated 
molecules. 
 
 
6.7   Chromatin modification agents improve activation of DNA repair 
proteins. 
Since chromatin modification is important for the recruitment of DNA 
repair proteins to the DNA damage site, we suspect that the impaired 
recruitment of DNA repair proteins to DSB sites in ZNF668 depletion cells is due 
to the lack of efficient chromatin modification. To test this hypothesis, firstly, we 
tested whether chromatin modification reagents (sodium butyrate, NaB or 
trichostatin A, TSA) can reverse the effects of ZNF668 depletion on DNA repair 
protein activation and recruitments to DNA damage sites. The treatment of 
chromatin modification agents significantly reversed the effects of ZNF668 
depletion on RPA phosphorylation and foci formation (Figure 37A, B and C).  
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Figure 37. Chromatin modification agents improve activation DNA repair protein 
RPA. (A) Sodium butyrate (NaB) or trichostatin A (TSA) -induced chromatin 
modification restored the effect of ZNF668-depletion on RPA phosphorylation. 
ZNF668 knockdown cells were exposed to 50 J/m2 of UV irradiation in the 
presence or absence of chromatin modification reagents (NaB, 5 Mm; TSA, 200 
ng/ml). Cell lysates were prepared and subjected to Western blotting analysis 3 
hr after irradiation. (B) Sodium butyrate (NaB)-induced chromatin modification 
improved p-RPA34 foci formation in ZNF668-depletion cells. ZNF668 
knockdown cells were exposed to 50 J/m2 of UV irradiation in the presence or 
absence of NaB. Cells were prepared and subjected to immunostaining 3 hr 
after irradiation. Representative immunostaining images. Scale bar is 10 μM. (C) 
Quantitative analysis of p-RPA34 foci induced in ZNF668-depletion cells from 
multiple experiments. At least 50 cells were scored in each sample. Western 
blotting analysis showed the effective ZNF668 knockdown in the cells was 
shown above the graph. 
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Consistently, the treatment of chromatin modification agents also 
significantly reversed the effects of ZNF668 depletion on Rad51 foci formation 
(Figure 38A and B).  
 
 
 
Figure 38. Chromatin modification agents improve activation of DNA repair 
protein RAD51. (A) Sodium butyrate (NaB)-induced chromatin modification 
improved Rad51 foci formation in ZNF668-depletion cells. ZNF668 knockdown 
cells were exposed to 10Gy of IR irradiation in the presence or absence of NaB. 
Cells were prepared and subjected to immunostaining 3 hr after irradiation. 
Representative immunostaining images. Scale bar is 10 μM. (B) Quantitative 
analysis of Rad51 foci induced in ZNF668-depletion cells from multiple 
experiments. At least 50 cells were scored in each sample.  
 
 
Furthermore, the treatment of chromatin modification agents recovered 
RPA and p-RPA recruitment to the chromatin (Figure 39A). The reduced HR 
repair efficiency in ZNF668 knockdown cells was reversed in the presence of 
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chromatin modification agents (Figure 39B). These data indicate that the 
impaired HR repair and compromised recruitment of DNA repair proteins is a 
direct consequence of impaired access to chromatin in ZNF668-deficient cells. 
 
 
 
 
Figure 39. Chromatin modification agents improve recruitment of DNA repair 
proteins to chromatin and recover HR repair. (A) Sodium butyrate (NaB)-induced 
chromatin modification improved chromatin-associated p-RPA34 and RPA34 in 
ZNF668-depletion cells. ZNF668 knockdown cells were treated with 50 J/m2 of 
UV irradiation in the presence or absence of sodium butyrate (5mM). Three 
hours after treatment, chromatin-enriched fractions were subjected to Western 
blot analysis.  (B) Sodium butyrate (NaB) or trichostatin A (TSA) -induced 
chromatin modification restored the impaired HR repair in ZNF668-depletion 
cells. ZNF668-depleted cells were subjected to HR repair analysis in the 
presence or absence of chromatin modification reagents. Each value is relative 
to the percentage of GFP+ cells in I-SceI-transfected cells with control siRNA 
transfection, which was set to 1 and represents the mean ± SD of three 
independent experiments; Student’s t-test. 
 
 
6.8       ZNF668 depletion impairs histone H2A acetylation 
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Histone acetylation is important for chromatin modification after DNA 
damage response. Since we observed that the compromised HR repair in 
ZNF668 deficient cells was associated with impaired chromatin access for repair 
proteins, we reasoned that this may be due to impaired regulation of histone 
acetylation in the absence of ZNF668.  
To test this, we examined the histone acetylation in ZNF668 depletion 
cells.  We found that both the overall and IR-induced H2A K5 acetylation in 
whole cell lysates (extracted by SDS sample buffer) were affected by ZNF668 
depletion (Figure 40), which indicated that ZNF668-mediated H2A acetylation 
may have a role in DSB repair.  
 
 
Figure 40. Analysis of histone H2A acetylation following DNA damage in cells 
lacking ZNF668. ZNF668-containing and ZNF668-depletion U2OS cells were 
exposed to irradiation and cell lyses were prepared at the indicated time points 
after treatment. Cell lyses were subjected to Western blot analyses and 
immunoblotted with antibodies against the indicated molecules. H2A acetylation 
was analyzed. 
 
 79
Next, we examined whether the chromatin modification reagents can 
recover ZNF668’s effect on the impaired H2A acetylation at K5 site. The 
treatment of chromatin modification agents significantly reversed the effects of 
ZNF668 depletion on H2A acetylation at the K5 site after IR treatment (Figure 
41).  
 
 
Figure 41. Chromatin modification reagents sodium butyrate (NaB) or 
trichostatin A (TSA) -induced chromatin modification restored the effect of 
ZNF668-depletion on H2A acetylation after IR. ZNF668 knockdown cells were 
exposed to 10Gy of IR irradiation in the presence or absence of chromatin 
modification reagents (NaB, 5 Mm; TSA, 200 ng/ml). Cell lysates were prepared 
and subjected to Western blotting analysis 2 hr after irradiation. 
 
 
The acetylation site K5 is conserved in H2A and its viarant H2AX.  
Previous studies showed H2AX K5 is the target of acetylation upon DSBs in the 
chromatin because the IR-induced acetylation was abolished by the H2AX (K5R) 
mutation (Ikura et al., 2007). To clarify whether H2AX acetylation is the target of 
ZNF668 regulated acetylation process, we overexpressed Flag-H2AX in U2OS 
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cells and pull down the Flag-H2AX protein complex by immunoprecipitation. The 
Flag-H2AX acetylation was detected with K5 acetylation antibody. As shown in 
Figure 42, we found that H2AX K5 acetylation was induced by IR treatment and 
in ZNF668 depletion cells, the K5 acetylation of H2AX was significantly reduced. 
These data are consistent with the previous finding and indicate that ZNF668 is 
important for efficient H2AX K5 acetylation after IR DNA damage.  
 
 
 
Figure 42. ZNF668 depletion impairs IR induced H2AX acetylation. U2OS cells 
were transfected with control or ZNF668 siRNA; 24h later, cells were transfected 
with empty vector or Flag-H2AX; 48 h later, cells were exposed to IR treatment 
and cells were harvest at indicated time post-IR treatment. (A) Total cell lysates 
were subjected to western blotting analysis to confirm efficient ZNF668 
knockdown. (B) The cell lysates (1.5 mg) were immunoprecipitated and 
immunoblotted with antibodies against the indicated molecules. 
 
 
6.9   ZNF668 depletion impairs histone H2AX acetylation by regulating 
Tip60-H2AX interaction. 
Histone H2AX acetylation plays a role in the selective histone variant 
exchange, which is important for chromatin structure regulation at DNA damage 
sites (Kusch et al., 2004). Since we observed decreased histone H2AX 
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acetylation in ZNF668-depletion cells, we suspect that ZNF668 is important for 
histone H2AX acetylation and chromatin structure regulation.  
To test how ZNF668 regulates H2AX acetylation, firstly we tested whether 
ZNF668 interacted with H2AX. As shown in Figure 43, immunoprecipitation 
analysis showed that H2AX interacted with ZNF668. 
 
 
 
Figure 43. ZNF668 associates with H2AX. U2OS cells were transfected with 
empty vector or Flag-ZNF668; 48 h later, cells lysates (3 mg) were 
immunoprecipitated and immunoblotted with antibodies against the indicated 
molecules. 
 
Previous studies have shown that K5 of histone H2A is acetylated by 
Tip60 in vitro (Kimura et al., 1998).  The interaction between Tip60 and H2AX is 
IR-induced. After IR treatment, Tip60 specifically binds to H2AX but not H2A and 
facilitates H2AX K5 acetylation (Ikura et al., 2000). Since we observed 
decreased acetylation of H2AX K5 in ZNF668 depletion cells after IR, we 
suspect that ZNF668 regulates H2AX acetylation through the regulation of 
Tip60-H2AX protein complex. To test this, firstly, we tested whether ZNF668 
regulates Tip60 expression. As shown in Figure 44A, Tip60 protein level didn’t 
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change in ZNF668-depletion cells with or without IR treatment. Chromatin 
fractionation analysis also showed that the chromatin associated Tip60 didn’t 
change with ZNF668 knockdown and IR treatment (Figure 44B). 
 
 
 
Figure 44. Tip60 expression and chromatin association in ZNF668-depletion 
cells. (A) ZNF668 depletion didn’t impair Tip60 expression with or without IR. 
ZNF668-containing and ZNF668-depletion U2OS cells were exposed to IR. Total 
cell lysate were harvested in urea buffer at the indicated time points and 
subjected to Western blot analyses. (B) Tip60’s association with chromatin were 
similar in control and ZNF668-depletion cells. ZNF668-containing and ZNF668-
depletion U2OS cells were exposed to IR. The chromatin fraction was prepared 
and subjected to Western blot analyses.  
 
 
To test whether the reduced H2AX acetylation in ZNF668-deficient cells is 
due to the decreased interaction between Tip60 and H2AX proteins, we did 
immunoprecipitation assay of FLAG-H2AX protein complex. As shown in Figure 
45A, the interaction between H2AX and Tip60 was induced by IR treatment in 
control cells, which was consistent with previous finding (Ikura et al., 2007). 
However, ZNF668-depletion impaired the IR-induced interaction between Tip60 
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and H2AX, indicating ZNF668 is required for facilitating Tip60 interaction with 
H2AX to acetylate H2AX after DNA damage treatment (Figure 45B). 
 
 
 
Figure 45. ZNF668 depletion impairs IR induced Tip60-H2AX interaction. (A) 
U2OS cells were transfected with Flag-H2AX and exposed to IR treatment 48 
hours after transfection. Cell lysates were harvested at indicated time post-IR 
treatment and subjected to immunoprecipitation and immunoblotting. (B) U2OS 
cells were transfected with control or ZNF668 siRNA; 24h later, cells were 
transfected with empty vector or Flag-H2AX; 48 h later, cells were exposed to IR 
treatment and cells were harvest at 30 minutes post-IR treatment. The cell 
lysates (1.5 mg) were immunoprecipitated and immunoblotted with antibodies 
against the indicated molecules. 
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6.10 Discussion 
In this part of study, we studied the function of ZNF668 in DNA damage 
response pathways. Our data indicated that ZNF668 didn’t affect the initiation 
and signaling cascade of DNA damage pathway. However, ZNF668 participated 
in DNA damage repair. The inefficient DNA repair in ZNF668 depletion cells 
caused prolonged DNA damage and genetic instability. 
Chromatin modification is important for efficient DNA damage repair 
proteins’ recruitment to the damage sites. Our data showed that ZNF668 is a 
chromatin associating protein (Figure 36A) and it interacts with histone variant 
H2AX (Figure 43). ZNF668 didn’t affect H2AX activation but it affects histone 
H2AX acetylation upon DNA damage treatment, which is important for the open 
of chromatin structure upon DNA damage treatment and the access of repair 
proteins to the damaged DNA. Therefore, our results suggest a model for 
ZNF668 function in double strand break repair. ZNF668 promotes chromatin 
modification and in turn facilitates the recruitment of DNA repair proteins to DNA 
lesions for efficient repair. Loss of ZNF668 would lead to impaired chromatin 
modification and DNA DSB repair, which may contribute to the development of 
cancer. 
Our findings also reveal a mechanism by which ZNF668 regulates 
chromatin modification. Different types of histone acetylase are responsible for 
the acetylation of different histones (Tsukuda et al., 2005; Ziv et al., 2006; 
Peterson et al., 2000). With DNA damage, the Tip60 acetylase is recruited to 
DNA lesions by other molecules to recognize histone H2AX and induce H2AX 
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modifications. Our studies demonstrate that ZNF668 is necessary for the 
recruitment of Tip60 to the DNA damage site to perform its function on H2AX 
acetylation. Therefore it will be of future interests to address the underlying 
mechanism of ZNF668 regulation on Tip60-H2AX complex and illustrate the 
additional roles of ZNF668 in the regulation of Tip60-H2AX complex in response 
to DNA double strand breaks induced by DNA damage. 
The present study shows that ZNF668 participates in homologous 
recombination repair by regulating histone modification and chromatin 
remodeling. We propose a model (Figure 46) to explain the mechanism of 
ZNF668 in regulation of DNA repair. ZNF668 is a chromatin association protein. 
When the double strand breaks are induced by DNA damage treatment, ZNF668 
binds to histone H2AX around the DSBs. The protein complex of ZNF668-H2AX 
serves as a platform to recruit HAT-Tip60 to the DSBs. Then Tip60 acetylates 
H2A that surrounds DNA breaks. Acetylated histones facilitate access and 
binding of DNA repair proteins to chromatin DNA. After DNA repair is completed, 
the chromatin is reassembled. It has been shown that HAT complexes are 
related to cancer development because they are important for transcription 
regulation and regulation of DNA damage response (Cairns et al., 2001; Yang et 
al., 2004). Therefore, our studies identify a novel factor with the potential to 
regulate histone acetylation and chromatin remodelling during DNA repair and to 
maintain genomic stability. 
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Figure 46. A schematic model for the role of ZNF668-mediated histone 
acetylation and chromatin reconfiguration in DNA repair.  
 
 
Together, these results indicate that ZNF668 participates in chromatin 
modification and reconfiguration, which facilitate access of the repair machinery 
to the site of DNA breaks. However, further experiments will be needed to 
emphasize the role of ZNF668 in DNA double strand break repair. In addition to 
the DNA damage induced H2A acetylation, we also observed an overall 
decrease of H2A acetylation in ZNF668 deficient cells without DNA damage, 
indicating ZNF668 may also participate in the regulation of global acetylation. To 
further clarify the role of ZNF668 in DNA Damage site modification or global 
modification, chromatin immunoprecipitation (ChIP) and PCR techniques can be 
used to determine the recruitment of specific molecules such as Tip60, 
acetylated H2AX, acetylated H3 and H4 to the double strand break sites. The 
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U2OS cells that used in our study to study the HR repair provides us a useful 
tool to investigate the status of specific proteins in DSB sites. The DSB can be 
induced by I-SCE enzyme transfection and the primers flanking the DSB sites 
can be used to analyze the recruitment of proteins to the DSB sites after ChIP. 
In this study, we emphasized on the acetylation status of K5 site in H2AX 
in ZNF668 deficient cells because the role of H2AX K5 acetylation in DNA repair 
has been reported previously. However, there are other acetylation sites in 
H2AX such as K9. It is important to determine whether ZNF668 affects other 
sites of H2AX acetylation. This ambiguity can be resolved by examining site-
specific mutants in the histone proteins themselves. For example, K5 or K9 site-
specific H2AX mutants can be generated through site-directed mutagenesis and 
the acetylation status of mutant H2AX can be studied under DNA damage 
treatment with or without ZNF668 expression.  
In addition, our study doesn’t rule out the possible role of ZNF668 on 
other core histones’ acetylation. Many histone modifying enzymes have broad 
substrate specificities. For example, Tip60 can acetylate both H2A and H4. Due 
to this reason, it is difficult to discern the contributions of other histone 
acetylation to DNA repair. It is unclear whether ZNF668 regulates DNA repair 
through the regulation of Tip60’s acetylation effects on H2A or other histones. 
Antibodies specific to site-specific modifications of each core histone can be 
used to perform ChIP and PCR analyses to clarify the recruitment of histones to 
the DSB sites in ZNF668 deficient cells.  Moreover, future experiments will be 
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needed to identify the possibility of ZNF668’s effect on other type of histone 
modifications.  
Tumorigenesis is driven by the direct or indirect effects from the genetic 
alterations in oncogenes and tumor suppressor genes.  Our studies indicate 
ZNF668 is a potential tumor suppressor. In addition to the mutation inside 
ZNF668, it can also regulate other important genes involved in multiple 
pathways which are necessary for normal cell growth. These results make 
ZNF668 a potential therapeutic target for human breast cancer. Therefore, the 
novel findings from this project have both the potential to improve our 
understanding of genetic mechanisms underlying breast cancer and also the 
likelihood of novel approaches to the treatment of breast cancer. 
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